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Healthcare expenditures have been increasing rapidly in the Netherlands in the recent 
past. Major factors that drive healthcare spending are development and implementation 
of new expensive medical technologies, intensification of treatment and care and rising 
cost prices.1 In order to efficiently allocate scarce resources, policymakers are interested 
in the relative (cost-) effectiveness of medical interventions to ensure optimal priority 
setting. As a result, economic evaluations are increasingly important in healthcare 
decision making.
This dissertation reports on health economic studies of perioperative nutritional 
interventions in colorectal cancer (CRC) and esophageal cancer (EC). The first chapter 
opens with some background information on CRC and EC. Then, a brief description of 
recent randomized controlled trials (RCT) that investigate the effect of perioperative 
nutritional care on postoperative recovery is presented. The rationale and methods 
for economic evaluation and previous economic evaluations of nutritional care on CRC 
and EC patients are then discussed. Finally, the objectives and outline of this thesis are 
presented at the end of this chapter.
1.2. GASTROINTESTINAL CANCERS
1.2.1. Clinical and economic burden
CRC and EC are the most common and important cancers among gastrointestinal cancers.
Colorectal cancer (CRC)
More than 90% of CRC cases occur in people aged 50 or older.2 CRC is the second leading 
cause of cancer mortality and the third most common cancer worldwide.3 CRC impair 
the quality of life of patients with substantial symptoms such as abdominal pain, change 
in bowel movement, blood loss and anaemia, fatigue and weight loss. Furthermore, 
treatment brings upon a burden to quality of life by means of surgery, chemo- and 
radiotherapy. In the Netherlands, 76,488 people were suffering from CRC in 2017 and 
5,154 deaths were attributed to CRC in 2016,4, 5 suggesting an even higher incidence 
of CRC than in other Western European countries.6 CRC also represents a substantial 
economic burden for society. In 2017, in the Netherlands, annual healthcare costs of 
CRC were about 597 million euro, representing 0.7% of the total expenditure on the 
Dutch healthcare, and nearly 87% of these total costs were attributed to hospital costs.7
Esophageal cancer (EC)
EC is the sixth leading cause of cancer mortality and the eighth-most common cancer 
worldwide and has a poor prognosis.3 The quality of life is largely affected by the 
obstructing nature of the tumour and also by the complex treatment which may 
include chemotherapy or chemoradiotherapy in combination with surgical resection. 
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First clinical presentation of the disease often includes symptoms such as dysphagia, 
eating difficulties and appetite loss resulting in considerable weight loss and fatigue, 
and decreased quality of life and daily living. There is a rising incidence in EC in the 
Netherlands.8 with 5,467 people suffering from EC in 20189 and around 2,498 new 
cases identified in 2017.10 The Dutch healthcare costs for EC were 124 million euro for 
both men and women in 2007.1 This constitutes 0.17% of the total expenditure on the 
Dutch healthcare. Furthermore, CRC and EC patients have a high risk to suffer from 
disease related malnutrition due to changes in the metabolism induced by the disease. 
This can negatively influence the treatment and overall costs. The risk of postoperative 
complications also increases with a compromised nutritional status.11-13
1.2.2. Clinical management
Several studies have suggested that multimodality treatment consisting of (neo)
adjuvant chemotherapy, radiotherapy and surgery are the most effective treatment 
options for both EC and CRC.14-16
Surgical colorectal resection is a common treatment where the part of the colon and/
or rectum that contains the tumour is removed. Surgery for colon cancer is usually 
followed by adjuvant chemotherapy in case of node-positive disease. For rectal cancer, 
patients may be pre-treated with (neoadjuvant) radiotherapy or chemoradiotherapy. In 
case of EC, esophagectomy which is surgical resection of some or most of esophagus 
is a common treatment. Many advances have been made over the years focused on 
improving cancer-specific and overall survival, such as the introduction of neoadjuvant 
chemoradiotherapy17, transthoracic lymphadenectomy18 and advances in chemotherapy 
regimens.
Despite advances in surgical techniques and improvements in perioperative care, such 
as minimally invasive surgery and enhanced recovery after surgery (ERAS) programs, the 
incidence of postoperative complications following colorectal and esophageal surgery 
remains substantial.19-21 For EC, anastomotic leakage and pulmonary complications 
are the main factors for postoperative morbidity. 22, 23 Postoperative ileus (POI) and 
anastomotic leakage (AL) are major complications after colorectal surgery19-21 and occur 
in 30-46% of the patients24 leading to significant healthcare costs.25 Postoperative 
complications lead to a significant increase in the use of hospital resources such as 
laboratory and diagnostic tests, surgical reoperations and intensive care unit (ICU) 
stay. Rising expenses for complex medical procedures combined with limited resources 
represent a major challenge. In a study by Straatman et al.26, to assess the costs 
associated with complications after major abdominal surgery, major complications 
occurred in around twenty percent of patients and these patients account for more 
than 50% of the total costs.26 Another study by Volanthen et al. demonstrates that 




in-hospital costs.27 Furthermore, postoperative complications negatively impact the 
short- and long-term quality of life.22, 23, 28-32
ERAS protocols entail a combination of strategies such as early mobilization, limitation 
of surgical drains and most importantly early initiation of oral intake. Early start of 
enteral nutrition is an essential part of the ERAS program and has been shown to 
improve recovery.33 In the Netherlands, as in most European countries, oral intake is 
generally initiated 5 to 7 days after esophagectomy and oral intake is started directly 
after colorectal surgery. Studies have proven that there is no advantage of keeping 
the patient fasted after colorectal or esophageal surgery.34, 35 Early feeding reduces 
both the risk of infection and the length of hospital stay. Furthermore, early enteral 
nutrition has been shown to reduce POI and AL in rectal surgery.36 Previous studies 
have also proven that enteral nutrition reduces POI by reducing the inflammatory 
response via a mechanism that involves stimulation of the autonomic nervous system.37 
It remains unclear what the best strategy is for postoperative diet protocols in the early 
postoperative phase following surgical treatment.
Perioperative nutritional support has been introduced in many guidelines including 
ERAS. It is considered as a critical determinant in the outcomes of gastrointestinal 
surgery38 and has been shown to improve clinical outcomes and to reduce costs. 
Optimization of perioperative care by introduction of minimally invasive surgery, ERAS 
programs and patient prehabilitation is promising, suggesting a positive effect on clinical 
consequences.
1.2.3. Recent RCTs
Three new trials, SANICS I, SANICS II and NUTRIENT II were recently conducted by our 
group to investigate the clinical and economic effects of perioperative nutritional care 
on recovery following the surgical procedure.
1. A RCT to assess the effect of gum chewing on POI and inflammation in colorectal 
surgery (SANICS I trial). In this RCT, the impact of gum chewing on postoperative 
complications (POI) was studied.21 The trial proposed a simple and safe treatment where 
the patients were asked to chew gum before and after colorectal surgery to reduce POI 
and fasten recovery. Activation of the autonomic nervous system via the vagus nerve, 
which in turn brings a reduction in the systemic inflammation, was the main hypothesis 
in this trial. The trial compared the gum chewing group with the dermal patch (control 
group) which was placed on the lumbar back region 3 hours before surgery until the 
postoperative nutrition was initiated. The results of the trial report a reduction in the 
occurrences of POI and systemic inflammatory markers in the gum chewing group.21
2. Perioperative lipid-enriched nutrition versus standard care in patients undergoing 
elective, colorectal surgery (SANICS II): an international, multicentre, double-blinded 
11
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RCT was conducted in six hospital units in the Netherlands and Denmark.39 The 
trial investigated the effect of perioperative lipid-enriched enteral nutrition on the 
postoperative inflammation and complications when compared with standard care 
in patients undergoing colorectal surgery. Enteral nutrition was administrated before 
the start of the surgery, continued during the operation and was stopped six hours 
after the end of the surgical procedure. After this, the patients were offered oral intake 
following ERAS guidelines. The hypothesis of the trial was similar to the SANICS I trial 
to demonstrate the stimulation of the autonomic nervous system via the vagus nerve. 
The trial results, however, reported that perioperative enteral nutrition does not further 
improve the clinical outcomes when compared to modern practices in colorectal 
surgery.39
Gum chewing (sham feeding) and perioperative enteral nutrition are both examples 
designed to accomplish vagus nerve stimulation and achieve early recover after 
colorectal surgery.21, 39
3. Nutritional route in esophageal resection trial II (NUTRIENT II)40 is a multicentre open-
label RCT performed at two hospitals in the Netherlands and one hospital in Sweden. 
The trial aimed to investigate the effects of direct oral intake versus start of oral intake 
on postoperative day 5 on postoperative functional recovery following minimally 
invasive esophagectomy. Early start of oral intake is a critical part of ERAS protocols 
and beneficial in most types of gastrointestinal surgery. The feasibility and safety of such 
a nutritional protocol following esophagectomy was studied in the NUTRIENT I trial. 
The NUTRIENT II trial showed that direct oral intake following esophagectomy resulted 
in a similar time to functional recovery and did not result in an increase of severity of 
postoperative complications.41
Even though the clinical effects of these interventions are limited, it is important to 
assess economic implications of the interventions. Cost-effectiveness analyses help 
decision makers to efficiently allocate healthcare resources and are nowadays playing 
an increasing role in pricing and reimbursement decisions. Furthermore, it is important 
to investigate the societal costs of such interventions, that in some specific surgical 
patients with higher inflammatory response, could be largely beneficial.
1.2.4. Health economic studies
Economic studies (such as the burden of disease and economic evaluations) are 
becoming increasingly important in our healthcare system to promote more rational 
use of health resources.
Burden of disease
A burden of disease study focuses on the cost of illness and quality of life of a disease 




policy debates about resource allocation and research priorities.43 Cost data also 
provide inputs for inclusion in cost-effectiveness analyses used in promoting efficient 
healthcare.42
In economic studies, costs are identified in the following categories:44 A) Healthcare 
costs: These include all the costs in the healthcare sector including hospitalizations, 
medical procedures, and medications and all other costs during the study follow-
up such as prevention, diagnostics, therapy and rehabilitation costs. B) Patient and 
family costs: These include informal care costs, travel and time costs. C) Costs in other 
sectors: These include the productivity costs due to absence or inefficiency at paid and 
unpaid work, police and legal costs, special education and counseling. Resources can 
be measured using cost diaries or cost questionnaires. These measurement tools are 
especially important in measuring the costs outside the healthcare sector, as there may 
not be a database containing this type of information. The Dutch healthcare Institute 
has published the Guideline for Cost Research in the Netherlands for application of 
standardized costing methodology.45 The guideline also includes the reference prices 
for the common healthcare resources. The outcome of economic evaluation is typically 
expressed in QALY (quality-adjusted life years) that represents the impact of both 
quantity and quality of life. Utility measures are used to calculate QALYs and can be 
determined using preference based instruments such as EQ-5D.
Economic evaluations
An economic evaluation compares both the costs and effects of two or more 
interventions in a systematic manner which helps to evaluate the treatment that is 
more efficient.46 There are two methods to conduct an economic evaluation: trial-based 
economic evaluation and model-based economic evaluation.
In a trial-based economic evaluation, all the costs and effects data are measured 
simultaneously alongside the trial. It provides thus an early opportunity to produce 
estimates of cost-effectiveness. The results of this approach reflect data from actual 
patients. Most importantly, a trial-based economic evaluation entails to the collection 
of patient level data (for example, duration of hospital stays and types and quantities 
of services used over the follow-up period of the trial), and the internal validity of the 
data can be assessed through controlled clinical conditions. The perspective of the trial 
influences the categories of resource use that are included in the study. Dutch guidelines 
prescribe a societal perspective, which implies that all significant costs and benefits 
need to be included in the analyses regardless of where this fall.
Trial-based economic evaluation require the collection of resource use data from 
sources such as medical records, separate patient questionnaires or interviews with 
health professionals. The valuation of the resource use requires estimation of the unit 
cost for each element of resource use consumed by the patient. The unit costs tend to 
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be standardized across patients and trial centers. Apart from costs, consequences or 
outcomes of the alternatives should be examined in a trial-based economic evaluation. 
Outcome measures incorporated in a trial-based economic evaluation range from health 
endpoints (for example, hospital episodes avoided) to quality of life measures such as QALY.
Trial-based economic evaluation can be expressed as cost-effectiveness analysis and 
cost-utility analysis. In a cost-effectiveness analysis, outcomes are measured in natural 
units such as “length of hospital stay” or “change in occurrences of postoperative 
complications”. Hence, the outcomes are easily measured and interpreted in clinical 
practice. In a cost-utility analysis, which is the preferred type of trial-based economic 
evaluation, outcomes are measured in terms of health state preference weights or 
utility weights. The most common example of health utility is QALY. Despite some 
limitations of the trial-based economic evaluations such as inability to generalize the 
treatment pathways and patient samples to larger populations47, they provide relevant 
information by comparing the costs and consequences of alternatives.
Results of economic evaluation
To determine if a certain intervention is cost-effective, it is essential to calculate 
the incremental cost-effectiveness ratio (ICER). The extra costs that an intervention 
imposes over another are compared with the extra additional effects it brings. The 
additional costs and effects of intervention compared to control are determined using 
the following formula.
Where Costs intervention group and Costs control group represent the total costs during the period 
of the study and Effects intervention group and Effects control group represent the effects at the 
end of the follow-up.
For a graphical representation of the ICER, cost-effectiveness planes are commonly used 
to plot the costs against health effects. Costs are plotted on the y-axis and effects on the 
x-axis. A slope passing through the origin represents ICER. The cost-effectiveness plane is 
divided into four quadrants (see Figure 1). When the intervention is more effective and less 
costly than the comparator, the ICERs lie in the southeast quadrant and the intervention 
is considered dominant. Conversely, when the intervention is less effective and more 
costly, the ICERs lie in the northwest quadrant and the intervention is considered inferior. 
When the intervention is more costly and yet more effective, the ICERs lie in the northeast 
quadrant and when intervention is less costly and less effective, the ICERs lie in the 
southwest quadrant. Treatment is cost-effective when it is dominant. The implementation 
of a new treatment depends on the maximum amount of money that society is willing 




Figure 1. Example of a cost-effectiveness plane including fictional threshold.
Figure 2. Example of a cost-effectiveness acceptability curve. ICER, incremental cost-effectiveness ratio.
Furthermore, cost-effectiveness acceptability curves (CEAC) can be calculated which 
show that the probability that the treatment is cost-effective, given different ceiling 
ratios (Figure 2). Bootstrapping is a method used to investigate the uncertainty 
surrounding ICER. Bootstrapping is a simulation technique where a large number of 
new samples N (usually 5000 times) are created with replacement from the original 
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sample. This results in N different samples with each different ICER. ICERs are plotted 
on a CE plane to visualize the uncertainty around ICER. Additionally, 95% confidence 
interval can be calculated using the 2.5th and 97.5th percentile.
Although it is trivial to study the impact of interventions on the population, it is also 
of great significance to determine the role of different interventions to other socially 
desirable goals such as patient’s quality of life and reducing the societal costs.
1.2.5. Economic studies in CRC and EC
Previous studies have demonstrated a rising global burden of CRC.48-52 A study by Hall et 
al. showed a mean 15-month healthcare costs for CRC at £12,643 (€14,685) per patient 
and the majority of costs occurred at the primary treatment phase.48 An Asian study 
estimated direct medical costs at 24.81%, direct non-medical care costs at 38.04% and 
indirect costs at 37.14% of the total cost.49 Previous studies on health-related quality of 
life in CRC showed a utility of 0.67 during 0-6 months after diagnosis51 and 0.76 during 1 
year after diagnosis.52 However, variations in valuation methodology and cost estimation 
time frame were evident in these studies. Similarly the burden of esophageal carcinoma 
is expected to rise significantly and to continue to increase due to the growth and aging 
of the population. A study by Thein et al. demonstrated that costs were highest in the 
terminal phase and inpatient hospitalization cost was the greatest contributor to total 
costs.53
Few studies have examined the clinical and economic effects of various nutritional 
interventions in CRC/EC surgery. A study by Atkinson et al., comparing the gum chewing 
(starting one day after surgery) with standard care found no differences in net monetary 
benefit between the groups and concluded that gum chewing was not cost effective.54 In 
another retrospective analysis by Rinninella et al., patients were consequently enrolled 
in an intervention group (ERAS +Nutricatt protocol) and were compared to patients 
treated with standard ERAS protocol is. Nutricatt protocol consisted of nutritional 
prehabilitation before surgery and in the preoperative period. This study showed a 
significant decrease in the hospital costs, complications associated costs and length of 
stay in the intervention group were found.55 A previous study by Sun et al evaluating 
the impact of early oral feeding on postoperative complications following minimally 
invasive esophagectomy concluded that early oral feeding was non-inferior compared 
to the standard care and had an improved short term quality of life. However, there 
is a large variation between studies with regards to timing of interventions, control 
group definitions, clinical outcomes, cost perspective, the composition of nutritional 
supplements which make it difficult to interpret and compare the results accurately.
New trials were conducted (SANICS 1, SANICS II, and NUTRIENT II) by our team with 
new interventions and it is essential to conduct economic evaluations of the new trials 




1.3. OBJECTIVES OF THIS THESIS
Given the increasing burden of CRC and EC and the importance of economic 
considerations, this study aims to get insight into various aspects of economic analysis 
including the burden of disease and assessment of the cost-effectiveness of recent 
advances in the treatment of CRC/EC. More specifically, this thesis will compose of 
two parts:
1. To estimate the burden of preoperative CRC in terms of cost and quality of life and 
explore the burden of the postoperative complications of CRC. (Part I: Cost of illness/
burden of disease studies)
2. To assess the cost-effectiveness of the interventions tested in the three trials previously 
described: SANICS I, SANICS II and NUTRIENT II trials. (Part II: Economic evaluations)
1.4. OUTLINE OF THIS THESIS
To answer the first objective of the thesis, in chapter 2, Data on the preoperative 
societal burden of CRC and quality of life of the SANICS II trial population is provided. In 
chapter 3, postoperative complications following colorectal surgery in terms of clinical 
inflammation, quality of life and costs are being explored answering the first objective 
of the thesis.
With regard to the second objective of this thesis, the next 3 chapters, chapters 4 
to 6 are focused on economic evaluations. chapter 4 describes the design and cost-
effectiveness results of gum chewing for patients undergoing colorectal surgery. 
The study was conducted under a hospital perspective where the costs and effects 
of gum chewing were compared to standard care in patients undergoing colorectal 
surgery. Furthermore, health-related quality of life between the two treatment arms 
was compared. In chapter 5, the results of the trial-based economic evaluation of 
the SANICS II study are presented. The cost-effectiveness and cost-utility analysis of 
perioperative enteral nutrition compared to standard care in patients undergoing 
colorectal surgery were described. A societal perspective was adopted and quality of 
life comparisons between the groups was additionally analyzed. chapter 6 gives insight 
into the hospital costs and quality of life changes in patients undergoing esophagectomy 
using the data from the NUTRIENT II trial.
Finally, chapter 7 provides elaborate answers to the research questions addressed and 
discusses the merits and demerits of the research performed in this thesis.
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Objective: To assess the quality of life and societal costs of patients prior to colorectal 
surgery in the Netherlands.
Methods: This study is embedded in a previous randomized controlled trial (SANICS II). 
The quality of life was measured using EQ-5D-5L questionnaires. The iMTA medical 
consumption questionnaire (iMCQ) and the iMTA productivity costs questionnaire 
(iPCQ) were used to identify and measure healthcare and productivity costs. Subgroup 
analyses were performed based on age and gender.
Results: A total of 178 patients were included in the cost analysis and a total of 161 
patients in the quality of life analysis. The three-month mean societal cost per patient 
amounted to €3,211 of which €1,459 was due to productivity losses. The mean utility 
was 0.88 per patient. Gender was an important predictor in quality of life with men 
scoring significantly higher than women (0.92 versus 0.82) at p < 0.0001.
Conclusion: Colorectal cancer represents a high economic burden in the Netherlands. 
Further research with repeated cost and quality of life measurements would be needed 
to explore the change over time and the effects of surgery.
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2.1. INTRODUCTION
Colorectal cancer (CRC) is the third most common cancer (10% of the total) in men and 
second in women (9.2% of the total) worldwide.1 The incidence of CRC is higher in the 
Netherlands when compared to other countries in Western Europe.2 Nearly 15,427 new 
cases of CRC were reported in 2016 and the incidence has been steadily increasing at 
a rate of 13%-18% per year (1990–2016).3 Prevalence of CRC is further expected to rise 
as a result of national CRC screening and ageing Dutch population.4, 5
Survival rates have increased in patients with CRC due to improvements in (neo) 
adjuvant treatment and surgical approaches.6, 7 However, this is also accompanied with 
side effects including physical discomfort and difficulties in terms of life satisfaction8, 
depression9 and psychological distress10 which may ultimately lower the quality of life. 
Additionally, CRC imposes a significant economic burden for the patient and society.11, 
12 The economic burden of CRC is determined by many different factors and to better 
focus on what items may be important, the burden of disease (BoD) studies assessing 
the quality of life and financial aspects of a particular disease over a defined period of 
time are essential.13
Cost elements in BoD studies include healthcare costs, patient and family costs and 
productivity losses among patients and caregivers. There is limited information about 
cost and quality of life on CRC11, 12, 14 with very few or no studies from the Netherlands, 
especially the burden of CRC prior to surgery is largely unknown. To our knowledge, this 
is the first study to estimate the costs prior to colorectal surgery in the Netherlands. The 
aim of this study is, therefore, to estimate the societal costs and the quality of life of 
CRC patients prior to surgery. This study will further provide important results for future 
health economic analyses of new interventions in patients with CRC and increases the 







In this study, we estimated the costs in monetary terms and quality of life in utilities. 
Although other approaches are also well established, a bottom-up, prevalence-based 
approach from a societal perspective was used since this approach is considered as 
the most appropriate for assessing the cost of illness.15 This study is embedded in 
the SANICS II trial which is a multicenter randomized controlled trial, the details of 
which are described elsewhere.16, 17 In brief, the SANICS II study investigates the clinical 
effectiveness and cost-effectiveness of perioperative nutrition compared with standard 
care (nil by mouth) in patients undergoing colorectal surgery. In this study, we report 
costs and quality of life prior to colorectal surgery. Both the treatment arms were 
pooled for the purpose of this study.
2.2.2. Population and setting
Five hospitals (three hospitals from the Netherlands and two hospitals from Denmark) 
participated in the original trial. For this study, patients in Dutch hospitals only were 
included. Patients who are above 18 years of age and undergoing elective segmental 
colorectal resection with anastomosis were eligible for inclusion. Patients with previous 
gastric or esophageal resection, peritoneal carcinomatosis, pre-existent or creation 
of an ileostomy, steroid use, and use of medication that disrupts the acetylcholine 
metabolism were excluded. Furthermore, patients with the benign colorectal disease 
were excluded for this study. The medical ethics committee of Catharina Hospital 
(Eindhoven, the Netherlands) granted the approval for the original study. Written 
informed consent was obtained from all the included participants.
2.2.3. Data collection
Cost and quality of life were collected by means of questionnaires for the period 
between August 2014 and February 2017, at a single time point (baseline). The baseline 
questionnaires were handed out to the patients on the first day of their admission.
2.2.4. Cost perspective
The study followed the Dutch guidelines for health economic evaluations, which 
promotes cost calculation from a societal perspective meaning that all the healthcare 
costs and patient and family costs of CRC were accounted for.18
Cost estimation was followed in 3 steps namely:
1.Identification, 2. measurement and 3. Valuation.
Step I: Identification of costs:
Costs included were those related to preoperative CRC care and were categorized 
as 1. Healthcare cost (i.e. hospitalizations, medical procedures, medications etc.), 2. 
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Patient and family costs (i.e. Travel and time costs) and 3.Costs in other sectors (i.e. 
productivity costs). As there are no registrations available for time and travel costs, 
they were excluded.
Step II: Measurement of costs
Self-reported questionnaires for healthcare consumption and productivity losses were 
used in this study. The iMTA Medical consumption questionnaire (MCQ) was used 
to measure the healthcare utilization and the iMTA productivity cost questionnaire 
(PCQ) was used to measure the costs due to productivity losses in two domains related 
to 1) paid work due to absenteeism and presenteeism, and 2) unpaid work.19 Both 
the questionnaires are commonly used in the Netherlands to assess healthcare and 
productivity losses. These questionnaires are generic and the items are not related to 
any specific disorder. The recall period for the MCQ is 3 months and for the PCQ is 4 
weeks. The PCQ costs per patient were extrapolated to 3 months.
Step III: Valuation of costs
The costs were expressed and analyzed in Euros and were indexed for the year 2017. 
The updated Dutch Manual for Cost Analysis in Healthcare Research was used for the 
valuation of the healthcare costs.18 The identified health services consumed by the 
patient were multiplied with their corresponding unit prices. Total costs were estimated 
by summing the individual services. All medication costs were derived from the website 
with the official listing of drugs with prices: www.medicijnkosten.nl. Medication 
costs were based on the price per dosage of the drug in the Netherlands. In case of 
uncertainty regarding a medication, the lowest cost price was used. Medications with 
out a specific name were omitted (for example, when a patient mentions antibiotics or 
‘medicine for stomach protection’). Productivity losses were valued using the friction 
cost method which takes into account production losses confined to the period needed 
to replace the sick employee (85 days).20 Friction costs were applied to patients below 
the retirement age.
2.2.5. Quality of life perspective
Quality of life was assessed using the Dutch five level, five-dimensional EuroQoL (EQ-5D-
5L) questionnaire consisting of mobility, self-care, usual activities, pain/discomfort and 
anxiety/ depression. Each dimension was scored on a five-point scale which represented 
‘no problems’, ‘slight problems’, ‘moderate problems’, ‘severe problems’ and ‘extreme 
problems’. The 5 dimensions can be summed into a health state. Utility values can be 
calculated for these health states, using preferences elicited from a general population, 





All statistical analyses were performed using IBM SPSS Statistic V.24. For Windows 
(IBM corp., Armond, NY, USA). Since the cost data are typically highly skewed, non-
parametric bootstrapping (with 5000 replications) was used to estimate the 95% 
confidence intervals around the mean difference in all the cost categories. Subgroup 
analyses were performed according to the gender (male and female) and median age 
(older age group is >67 years; younger age group is <67 years). Age and gender are two 
potentially important demographic characteristics and were available in our study. 
Estimates such as means, medians, standard deviation and confidence intervals were 
reported. Mann-Whitney U test was used to compare the cost means.
2.4. RESULTS
2.4.1.Demographic characteristics
A total of 184 patients participated in the RCT of which 178 patients completed the 
cost questionnaires and 161 patients completed the EQ-5D-5L questionnaires. This is 
a complete case analysis and therefore we did not have any missing data in this study. 
More than half of them were men (n = 104; 64.59%) and the mean age of the patients 
was 67.55 years (SD 9.55). The number of patients in the younger age group was slightly 
higher than in the older age group (83 versus 78).
2.4.2. Costs
The mean societal cost per patient amounted to € 3,211 over a period of 3 months of 
which 45.4% (€1,459) was due to productivity losses. (Table 1). Total healthcare sector 
costs represented 54.5% (€1,752) of the total societal costs of which hospitalizations at 
23.9% (€420), visits to the outpatient clinic at 21.9% (€385) and treatment procedures 
at 20.8% (€365) were the main contributors (Table 1).
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Patients stayed on an average 0.9 days in a hospital and had 1.5 consults with allied 
health professionals (e.g. physiotherapist, social worker). Patients were unable to 
perform paid labor for 33.2 hours (4.15days) and unpaid labor for 12.4 hours (1.55 days). 
Nearly 67.9% of patients used general practitioner services and 84.8% had outpatient 
visits. Seven patients (3.9%) used ambulance service and 20 patients (11.2%) had 
emergency visits to the hospital. Forty three patients (24.1%) had a diagnostic test and 
25 patients (14%) had a treatment procedure per-formed in the three months prior to 
CRC surgery.
The younger age group showed societal costs at €4,449 compared to the older age group 
at €1,946 (p = 0.073). The mean general practitioner costs were significantly higher for 
the older age group (64 versus 43 at p = 0.014). Paid care and total productivity costs 
were also significantly higher for younger age group (2,548 versus 3 at p < 0.0001; 
and 2,752 versus 135 at p < 0.0001 respectively). The mean societal costs for men 
were €3,465 and that for women €2,759 with no statistical significance. Mean general 
practitioner care costs were significantly higher in women when compared to men (€74 
versus €42) at p = 0.003. Mean home care costs were significantly higher for women 
(€263 versus €85) at p = 0.016 (Table 2)
2.4.3. Utilities
The mean utility was 0.88 (SD: 0.15) per patient prior to intervention and surgery. 
Men had a significantly higher utility when compared to the women (0.92 versus 0.82) 
at p < 0.0001. The utilities for the younger and older age groups were not different 
between the groups (0.90 versus 0.86 p = 0.86). With regards to pain/discomfort, 24.2% 
of the total patients experienced slight problems. The frequency of five dimensions as 
measured using EQ-5D-5L questionnaires is reported in Table 3.
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Table 3. Frequency of reported problems by dimension
EQ-5D Dimension
No problems 129 (80.1%)
Slight problems 12 (7.5%)
Moderate problems 18 (11.2%)
Severe problems 1 (0.6%)
Unable to 1 (0.6%)
Total 161
No problems 155 (96.3%)
Slight problems 3 (1.9%)
Moderate problems 2 (1.2%)
Severe problems 0
Unable to 1 (0.6%)
Total 161
No problems 122 (75.8%)
Slight problems 23 (14.3%)
Moderate problems 11 (6.8%)
Severe problems 2 (1.2%)
Unable to 3 (1.9%)
Total 161
No pain 101 (62.7%)
Slight pain 39 (24.2%)
Moderate pain 18 (11.2%)
Severe pain 3 (1.9%)
Unable to 0
Total 161
No anxiety 128 (79.5%)
Slight slight anxiety 26 (16.1%)
Moderate anxiety 4 (2.5%)
Severe anxiety 2 (1.2%)








CRC represents a high economic burden in the Netherlands. In 2011, in the Netherlands, 
costs of CRC were about 488 million euros, that is 0.5% of the total healthcare costs and 
nearly 87% of these total costs were attributed to hospital costs.22 In this study, the mean 
societal cost per CRC patient was estimated at €3,211 in the 3 months prior to surgery. 
The productivity losses represent a major part of these costs at 45.4% of total costs.
In the UK, Hall et al estimated costs of cancer care with the healthcare perspective that 
showed mean 15-month cumulative healthcare costs for CRC at £12,643 (approximately 
€15,945) per patient and concluded that <65 age group incurred greater costs than 
the >65 years age group which is in line with our study.23 The study also demonstrated 
that the majority of the costs occurred within the first 6 months from diagnosis 
suggesting high costs during the primary treatment phase. Extracting the costs for 
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the 3-month period from this study (15,945/15*3) results in €3,189, very similar to the 
3-month societal costs in our study. An Asian study estimated direct medical costs 
at 24.81%, direct non-medical care costs at 38.04% and indirect costs at 37.14% of 
the total cost.24 In this study, direct medical costs (healthcare costs) comprised of 
54.5% and indirect costs (productivity costs) accounted for 45.4% of the total costs.
In another Finnish study by Niilo Farkkila, which estimates the costs CRC at different states 
of the disease, primary treatment (0–6 months after diagnosis) and advanced treatment 
states had the highest reported costs.25 The cost for the 6-month interval between diagnosis 
and treatment (primary treatment period) was €22,200 which included direct healthcare 
costs, informal care costs and productivity losses. Productivity losses caused by CRC was 
substantial at €5,098 at the primary treatment state.25 The overall costs vary depending on 
the number of years spent with CRC and degree of severity. It is therefore difficult to directly 
compare our study with this study and other previous studies due to various reasons. First, 
our study assessed the costs of patients for the period of 3 months and did not include 
the operative and postoperative costs which are considered to be the main cost drivers. 
Previous studies estimated total costs annually or longer than 12 months including surgery. 
Second, variations in valuation methodology such as using the human capital approach 
in previous studies and friction cost method in this study could affect the total costs. 
Higher productivity costs were estimated in Farkilla that used the human capital approach.
In our study, the quality of life scores was relatively high (0.88) and higher than the 
previous studies.14, 26 Comparison to utility values in other studies should however 
be interpreted with caution as different tariffs for EQ-5D-5L have been used. To our 
knowledge, no study is available with utility value of the general Dutch population. 
Further comparison with the general Dutch population would be worthwhile. A study 
by Farkkila estimating the health-related quality of life in CRC showed a utility value of 
0.760 in the primary treatment group (0–6 months after diagnosis).14 Similarly, another 
study evaluating nationwide health utility showed a score of 0.67 in the acute period 
(<1 year) after a colon cancer diagnosis.26 The high utility scores in our study could 
potentially be explained by the fact that our estimation was conducted just before 
surgery and that patients have a current better quality of life because of the surgery 
surveyance. Measurement of quality of life scores could also be biased or confounded 
due to the setting (hospital) or feelings of anxiety/excitement prior to surgery. The 
significant higher utility scores by men in our study could be explained by the fact that 
women usually self-report worse health than men.27, 28 It is however difficult to assess 
if the differences in utility values are clinically meaningful which is beyond the scope 
of this study and further research would be required to investigate this.
This study has several limitations. First, costs and quality were estimated only at one 
time point. Baseline questionnaires were filled out on median preoperative day 1 (range 




were 3 months and 4 weeks respectively and iPCQ was extrapolated to 3 months. 
Second, we used a self-reported questionnaire which is known to cause recall bias. 
Third, we did not estimate transportation fees and out of pocket expenses which may 
have led to an under-estimation of the total costs. Lastly, we recruited the patients 
from the clinical trial which may limit the generalizability of the results. Limited use 
of exclusion criteria was used in an attempt to increase the generalizability of results.
Considering the fact that the median duration from the time of diagnosis to initiation 
of treatment for CRC in the Netherlands is 21 median days,29 this paper provides an 
understanding of the initial costs of patients with CRC. The study reveals the importance of 
healthcare costs and productivity losses received by cancer patients. Earlier detection and 
improved treatments will hopefully lead to improved survival and reduced additional costs.
In conclusion, this study reveals that CRC costs impose substantial economic costs in the 
Netherlands. This study provides important information for future economic analyses 
and comparison of new interventions in patients with CRC. We recommend further 
research with larger sample and repeated cost and quality of life measurements to 
explore the change over time and the effects of surgery.
2.6. EXPERT OPINION
The economic burden of colorectal cancer is high. Important economic elements include 
healthcare costs and productivity losses among patients and caregivers. To date there 
is however, a scarcity of economic data and a large heterogeneity across studies is 
observed limiting comparisons. We recommend standardization of reporting and costing 
methods and development of data collection resources that improve the comparability 
of studies over time. In addition, to tackle colorectal cancer efficiently, we recommend 
to conduct cost-effectiveness analyses. Data from this article could serve as reference.
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Background: Colorectal surgery is associated with postoperative ileus (POI). Despite its 
widespread manifestation, the influence of POI on recovery, quality of life (QoL), and 
costs is largely unknown. The aim of this study was to assess whether the inflammatory 
processes found in experimental studies are also evident in patients undergoing 
colorectal surgery. In addition, the impact of POI on short and long-term QoL and 
costs was investigated.
Methods: We analyzed the outcomes of the SANICS-II trial, including prospective 
evaluation of inflammatory parameters in blood samples, costs from a societal 
perspective and QoL, using validated questionnaires. Outcomes were compared 
between patients with and without POI, and in particular patients with POI as unique 
complication.
Key Results: A total of 265 patients (POI, n=66 vs non-POI, n=199) were included 
and 38/66 had POI as only complication. CRP levels were significantly increased on 
postoperative day (POD)1, 2, 3 and 4 in patients with POI. Furthermore, plasma levels 
of cytokines IL-6, Il-8 and IL-10 were significantly increased the first two days after 
resection. Patients with POI had a higher overall complication rate and a reduced QoL 
3 months postoperatively, even in the only-POI group. Moreover, mean societal cost 
per patient with POI were 38-47% higher at 3 months postoperatively.
Conclusions & Inferences: Supporting findings from experimental studies, inflammatory 
parameters were increased in patients with only POI and comparable with all patients 
with POI. These results demonstrate the impact and large contribution of POI in 
postoperative inflammation, costs and QoL in patients undergoing colorectal surgery.
KEY POINTS
· Postoperative ileus (POI) is a common complication in patients, however translation 
of experimentally found mechanisms and resolutions to the clinical setting remain 
challenging.
· This study found that patients with POI had a higher inflammatory response, more 
complications, an increased length of stay, a decreased quality of life and more 
healthcare costs.
· This study confirms the association of POI with inflammation and demonstrates the 
burden of POI on patients, the healthcare system and society.
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3.1. INTRODUCTION
Colorectal surgery is associated with a substantial complication rate. In particular, 
postoperative ileus (POI) is affecting 10 - 40% of patients undergoing a colorectal 
resection and is an important clinical determinant of short-term morbidity.1 POI is often 
seen as an inevitable complication of abdominal surgery, and attempts have been made 
to reduce the incidence by Enhanced Recovery After Surgery protocols, less opioid use 
and studies investigating the use of chewing gum.2 Still, POI is leading to discomfort, 
impaired recovery, a prolonged length of hospital stay, reoperation and readmission.3, 4 
Notably, an association exists between POI and anastomotic leakage, further indicating 
the impact of POI on postoperative morbidity.5
Complications after colorectal surgery have impact on the quality of life (QoL) and 
are associated with a substantial increase in costs.6, 7 However, it is unknown what the 
significance of POI is in these costs and quality of life, in the short and long term after 
patients have been discharged. Furthermore, clinically relevant therapeutic strategies 
for POI are lacking, although the underlying mechanism of POI has been unraveled 
in rodent models.8 Such models point out that POI is triggered by local inflammatory 
infiltrates and is associated with systemic inflammatory markers. Manipulation of the 
intestine induces activation of macrophages, mast cells and enteric glial cells.9-11 Vagus 
nerve stimulation has been shown in experimental models to be effective in reducing 
the inflammatory process underlying POI.12 Also, stimulation of the vagus nerve via 
lipid-enriched nutrition, was effective in several experimental models, although such an 
effect of lipid-enriched nutrition was not observed in a large double-blind randomized 
controlled trial (SANICS II trial).13 However, despite the insight into molecular cues to 
POI development, little progress is made in translating these experimental findings to 
a clinical practice. The reason for this discrepancy between the experimental data and 
the implementation into clinical practice may be twofold; on the one hand there is a lack 
of consensus amongst physicians towards the clinical features of POI, its impact, and 
its management, resulting in few high quality clinical studies also in a surgical setting.14 
On the other hand, it is uncertain whether the mechanisms found in rodent models can 
be completely translated into the clinical setting.15-18 The aim of the current study is to 
address whether inflammatory processes such as those found in experimental studies, 
occur in patients undergoing colorectal surgery. In addition, the impact of POI on short 
and long-term QoL and costs was investigated.
3.2. MATERIALS AND METHODS
This is a sub-study from a previous international multicenter double-blind randomized 
controlled trial (SANICS II trial) in three Dutch hospitals and three Danish hospitals.13 
The trial was designed to compare lipid-rich nutrition administrated just before, during 




approved by the Medical Ethics Committee of the Catharina Hospital (Eindhoven, The 
Netherlands) and was reported according to the CONSORT guidelines. The principles 
of Good Clinical Practice and the Declaration of Helsinki were followed. The trial was 
registered with ClinicalTrials.gov (number NCT02175979) and trialregister.nl (number 
NTR4670). Further details regarding the trial design and outcomes have previously 
been reported.13, 19
3.2.1. Population and setting
In the SANICS II trial described earlier, 280 patients were randomized, 15 of whom 
were excluded after random allocation because they fulfilled one or more exclusion 
criteria. All 265 patients analyzed in the original trial were considered for inclusion in 
the current study. Briefly, inclusion criteria were age 18 years or older and undergoing 
elective segmental colorectal resection with primary anastomosis. The exclusion criteria 
were a previous gastric or esophageal resection, peritoneal metastases, a pre-existing 
or the creation of an ileostomy, and the use of glucocorticosteroids or medication 
that disrupted acetylcholine metabolism (e.g., selective serotonin reuptake inhibitors 
or anticonvulsants). All patients provided written informed consent. Patients were 
randomly assigned to the intervention or control group and stratification was applied 
to ensure an equal distribution between colonic and rectal surgery and between 
laparoscopic and open procedures. In the present study, patients were stratified into 
two groups including those with and without POI. First, in order to assess the true 
influence of POI, an analysis was performed in a selected group of patients in which 
patients with POI as unique complication (n=38/66) were compared with patients 
that did not develop any complications after surgery (n=144/199). Second, the total 
study population (n=265) was analyzed to investigate the contribution of POI to other 
complications, inflammation, QoL and costs.
3.2.2. Clinical outcomes
POI is the primary outcome in the original trial and is measured clinically. POI was scored 
by the definition as described by Vather et al.20 Patients had to meet the following 
criteria at postoperative day (POD) 4 after colorectal surgery: lack of flatus or stool 
passage and inability to tolerate a regular oral diet. We also included late POI which 
is established when the symptoms of POI (lack of flatus or stool passage and inability 
to tolerate an oral diet) are first experienced after POD 4. Patients were instructed 
to register presence of nausea or vomiting, passage of flatus and defecation, and 
consumption of a regular oral diet in a diary daily. All surgical complications within 
30 days postoperatively were registered and graded according to the Clavien–Dindo 
Classification of Surgical Complications.21 Secondary outcomes included length of stay, 
readmissions, health-related QoL and costs and the inflammatory response.
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3.2.3. Measurement of the inflammatory response
Blood samples were collected from all patients at four predefined time points. Samples 
were taken the day before surgery and 4, 24 and 48 hours after onset of surgery. All 
the blood samples were immediately put on ice, centrifuged at 4⁰C and 3000 g for 12 
minutes and the plasma was stored at −80°C until further analysis. To determine the 
most important inflammatory cytokines, a Human Inflammatory Cytokines Kit was used 
to measure cytokine levels of IL-1β, IL-6, IL-10, IL-8, IL12p70 and TNF-α by cytometric 
bead array (BD Biosciences, Erenbodengem, Belgium) according to manufacturer’s 
instructions. CRP (C-reactive protein) measurement was part of the standardized 
care and the outcomes were retrieved from the medical chart. As such, CRP was only 
measured postoperatively, on postoperative day (POD) 1, 2, 3 and 4. CRP levels were 
determined by an immunoturbodimetric assay (Roche/Hitachi cobas c system, Roche, 
Rotkreuz, Switzerland).
Data on costs and QoL were collected by means of questionnaires for the period 
between August 2014 and August 2017, at three time points namely preoperatively, at 
3 months and at 6 months postoperatively. Patients who completed the questionnaires 
at least at two time points were included for this analysis.
3.2.4. Costs
The Institute for Medical Technology Assessment (iMTA) Medical consumption 
questionnaire (iMCQ) was used to measure the healthcare costs; these include 
hospitalizations, medical procedures, medications, outpatient clinic visits etc. The 
iMTA productivity cost questionnaire (iPCQ) was used to measure the costs due to 
productivity losses in two domains 1) paid work due to absenteeism and presentism 
and 2) unpaid work.22 The costs were expressed and analyzed in Euros. The updated 
Dutch manual for Costing Analysis in Healthcare Research was used for valuation of the 
healthcare costs.23 Costs were divided into three categories: 1) healthcare sector costs; 
2) costs for patient and family; and 3) productivity costs. Healthcare costs consisted 
of medication costs, consultations with healthcare professionals, use of diagnostic 
methods and the frequency of inpatient stay and outpatient treatment. The identified 
health services consumed by the patient were multiplied with their corresponding unit 
prices. Total costs were estimated by summing the individual services. Medication costs 
were based on the price per dosage of the drug in the Netherlands. Patient and family 
costs included the use of formal (paid care) and informal care (unpaid care). The costs 
for unpaid care were valued using the proxy good method, which values the time spent 
on informal care at the labor market price of a close market substitute. Productivity 
costs included productivity losses due to absence from work and were valued using 
friction cost method. The friction cost method which takes into account production 




3.2.5. Quality of life and utilities
QoL was assessed using the five level, five dimensional EQ-5D-5L, which is a standardized 
measure of health status developed by the Euroqol group. EQ-5D-5L consists of mobility, 
self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension 
was scored on a five-point scale which represented ‘no problems’, ‘slight problems’, 
‘moderate problems’, ‘severe problems’, and ‘extreme problems’. Utilities were derived 
from EQ-5D-5L using Dutch tariffs.24 The five dimensions can be summed into a health 
state. Utility values can be calculated for these health states, using preferences 
elicited from a general population, the so called Dutch algorithm. Here, utility is used 
to measure a single value between 0 and 1, that reflects the health-related quality of 
life of the patient.
In colorectal cancer patients, QoL was further assessed using the European Organization 
for the Research and Treatment of Cancer Quality of life Questionnaire Cancer Core-30 
(EORTC QLQ C-30). The scale ranges from 0 to 100, with higher scores indicating higher 
level of functioning for Global Quality of Life, Physical, Role, Emotional, Cognitive and 
Social Functioning and Fatigue. For financial problems higher scores indicate increased 
difficulty.
3.3. STATISTICAL METHODS
All statistical data were analyzed using SPSS V.25 (IBM, Armonk, NY, USA). Graphics were 
conducted with GraphPad Prism version 7 (GraphPad Software, La Jolla, CA, USA) Cost 
data are presented as means with 95% confidence interval and unpaired t-test was used 
to compare the cost means.25 To compare continuous data between groups, the data 
were tested for normal distribution (with skewness and kurtosis). Consequently, the 
Mann–Whitney U test was used for utility and inflammatory parameters, and the data 
were presented as medians. Analyses of inflammatory parameters were predefined in 
the protocol and chosen according to literature.11, 15, 26 Inflammatory parameters were 
treated as independent samples, CRP and cytokine measurements were compared per 
time point for the chosen conditions and no multiple comparisons have been applied. 
Univariate logistic regression was used to identify risk factors on POI. A multivariable 
logistic regression model was developed using factors identified as significant in 
univariate analyses as well as clinically relevant factors, including the following 
variables: American Society of Anesthesiologists (ASA) grade, colon or rectal surgery, 
open or laparoscopic surgical approach, duration of surgery, intraoperative blood loss 
and opioid use postoperatively. A two-tailed P value < 0.05 was considered significant.
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3.4. RESULTS
A total of 265 patients were included in this study. Patients with only POI (n=38) were 
compared to patients without developing any complication (n=144). Furthermore, 66 
patients in total met the criteria of POI, and 199 patients did not have POI. In the group 
of patients with only POI, 17/38 were operated laparoscopically (45%), and in the group 
without complications laparoscopic surgery was performed in 95/144 patients (66%). 
Demographics and clinical characteristics are outlined in Table 1
Multivariate logistic regression analysis showed that ASA-III grade (OR 4.08 CI 0.64-6.80 
P = 0.002), smoking (OR 4.13 CI 1.40-11.84 P = 0.008) and duration of surgery in minutes 
(OR 1.01 CI 1.00-1.02 P = 0.018) were associated with POI. To evaluate the systemic 
inflammatory response to surgery, CRP was routinely measured postoperatively and 
was significantly increased on postoperative day (POD) 1, POD2, POD3 and POD4 in 
patients with only POI compared to patients without complications (P = 0.016, P < 
0.001, P = 0.001, P = 0.047 respectively) (Figure 1A). On predefined time points for every 
patient plasma cytokine measurements were performed. As expected, preoperative 
cytokine levels were not different in patients with or without POI. Four hours after start 
of surgery, a trend towards higher IL-6 for patients with only POI was shown (P = 0.054). 
Moreover, at 24 - 48 hours after surgery, cytokine levels showed an increase in patients 
with POI as only complication. The most pronounced difference between only-POI and 
patients without complications was shown in IL-6 levels (24 h: P = 0.027; 48 h: P = 0.016). 
Furthermore, patients who only developed POI as complication had elevated levels of 
IL-8 at 24 h (P = 0.047) and 48 h (P = 0.015) compared to patients without complications. 
Also, levels of IL-10 were significantly elevated in patients with only POI compared 
to no complications at 48 h: P = 0.012 (Figure 1B-D). IL-1β, TNF-a and IL-12p70 were 
not different between groups, however concentrations in most samples were below 
detection limit (Figure 1E-G).
Results of the analysis of the total study population, including patients that had 
other complications as well, were comparable with the results of the only POI and no 
complications groups. CRP was significantly increased on POD 2, 3 and 4 in patients 
with POI compared to patients without POI (POD2: P < 0.001; POD3: P < 0.001; POD4: 
P = 0.003) (Figure 2A). Subsequently, levels of IL-6 (24 h: P = 0.017 and at 48 hr: 
P = 0.003), IL-8 (48 h: P = 0.001) and IL-10 (24 h: P = 0.036 and 48 hr: P = 0.003) were 
elevated significantly in patients who developed POI compared to patients without 





Table 1. Demographic characteristics
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Figure 1. Analysis showing perioperative circulating CRP and cytokine levels in patients with only post-
operative ileus (POI) (n=38) against patients without complications (n=144). Every single dot represents 
a patient, the bar indicates the mean. CRP was significantly elevated on postoperative day (POD) 1, 
2, 3 and 4 in patients with only POI. IL-6 and IL-8 showed a significant increase 24 hours and 48 hours 




Figure 2. Perioperative circulating CRP and cytokine levels in patients with (n=66) and without 
postoperative ileus (POI) (n=199), every single dot represents a patient, the bar indicates the 
mean. CRP was significantly elevated on postoperative day (POD) 2, 3 and 4 in patients with POI. 
IL-6 and IL-10 showed a significant increase 24 hours and 48 hours after surgery, IL-8 after 48 
hours (Mann-Whitney U test). *P < 0.05, ** P < 0.01, and *** P < 0.001.
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3.4.1. Costs and QoL assessments
In total 259/265 (98%) patients completed the questionnaires at baseline, 85% (224/265) 
of the questionnaires were completed postoperatively at 3 months and 82% (216/265) 
at 6 months postoperatively. Thirty-two patients with missing questionnaires at two 
time points were excluded from the analysis. This resulted in a total of 233 (88%) 
patients to be included in the analysis, of which 53 patients were reported with POI 
and 180 patients without POI. Of these, 32 patients had POI as only complication and 
133 had an uncomplicated recovery. Furthermore 15 patients with a non-malignant 
disease were excluded from the EORTC analysis.
3.4.2. Costs
Costs were calculated from a societal perspective meaning that all the monetary 
benefits were included regardless of who pays the costs and who gain the benefits. At 3 
months postoperatively, mean societal cost per patient was 38% higher for patients with 
POI as the only postoperative complication compared to patients without complications 
(€10647 vs €6606; P = 0.022; Table 2). Moreover, analyses of all patients with POI 
showed 47% higher mean societal costs than for all patients without POI (€14529 vs 
€7702; P < 0.001; Table 2).
3.4.3. Quality of life
Median utility score was significantly lower three months postoperatively in patients 
with only POI (0.85 IQR 0.76 – 0.98), compared to patients without complications (0.89 
IQR 0.83 - 1; P = 0.023). This effect was even more remarkable in all patients with POI at 
3 months, who scored significantly lower on health-related QoL than patients without 
POI (utility score 0.85 IQR 0.75 - 0.91 vs 0.89 IQR 0.81 - 1; P = 0.002). This difference was 
also apparent at 6 months postoperatively; the utility score in patients with POI was 0.84 
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Table 3. Complications
Considering the EQ-5D-5L health profile levels (no problems = level 1 and 
problems = levels 2 to 5) patients with POI as only complication were more likely to 
experience at least some problems relative to patients without complications. This 
effect was mostly shown in the dimensions mobility, usual activity and pain. Patients 
with only POI experienced more mobility problems (47%) than patients without 
complications (27%) at 3 months and even more at 6 months (66% vs 32%). The same 
was shown in usual activity: at 3 months 66% of patients with only POI vs 37% of 
patients without complications experienced problems and at 6 months 56% vs 38% 
experienced problems in usual activity, respectively. Pain did still impact QoL at 3 
months in 63% (only POI) vs 48% (no complications). Accordingly, in the total analysis, 
half of the patients with a period of POI experienced problems in mobility at 3 months 
(49% POI vs 32% no POI) and at 6 months this increased until 60% in POI patients and 
36% in patients without POI. This trend was also shown in problems in usual activity: 
68% (POI) versus 43% (no POI) at 3 months, and at 6 months 60% (POI) versus 43% (no 
POI). Pain did still impact QoL at 3 months in 66% of all the patients with POI, while in 
49% of patients without POI. (Table S2 supplementary data)
The EORTC-QLQ-C30 indicates the level of functioning in patients. At 3 months, patients 
with POI as only complication had significantly lower scores in Physical functioning and 
Role functioning than patients without complications. At 6 months, patients with only 
POI still had lower scores on Physical functioning (Figure 3). When other complications 
were included, patients with POI had lower scores on Global quality of life, Physical 
functioning, and Role functioning at 3 months, and still experienced lower scores 
on Global quality of life and Role functioning, and also in Emotional functioning at 6 




Figure 3. EORTC-QLQ-C30 level of functioning in categories measured at baseline, three months 
and six months after surgery in patients with POI as unique complication versus patients with no 
complications and all POI versus non-POI patients. Higher scores indicate higher levels of function-
ing except for financial difficulties. Data are medians (dots) and ranges. § P<0.05, §§ P<0.01 and §§§ 
P<0.001 for only POI (●) vs no complications (▲). *P<0.005 and **P<0.01 for all POI (●) vs no POI (▲).
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3.4.4. Complications, length of stay and readmission
The observation of elevated inflammatory biomarkers in patients suffering from POI, 
was also associated with a higher complication rate. Patients with POI experienced 
more complications than patients without POI; 42% (28/66) of the patients with POI had 
one or more accompanying complications, compared to 28% (55/199) of the patients 
without POI that had a complication (P = 0.025). Multivariate logistic regression analysis 
showed that ASA-III grade (OR 4.53 CI 1.61-12.75 P = 0.004) and duration of surgery in 
minutes (OR 1.01 CI 1.00-1.01 P < 0.001) were associated with POI in the total study 
population. Corrected for ASA-grade, smoking and duration of surgery, patients with 
POI remained at risk to have one or more accompanying complications (OR 2.31 CI 
1.25-4.27 P = 0.007). In addition, POI patients had a significantly higher number of 
complications (Table 3) and more severe complications, graded by the Clavien-Dindo 
classification: 17% (11/66) of the patients with POI had a Clavien-Dindo grade 3b or 
higher complication versus 8% (15/199) of patients without POI (P = 0.031). This means 
that patients with POI experienced another complication more often, either for which 
an intervention under general anesthesia was required, or leading to ICU admission 
or to death. In more detail, 14/66 POI patients also developed anastomotic leakage, 
against 9/199 of non-POI patients (P < 0.001), and 9 vs 4 patients developed pneumonia, 
respectively (P = 0.001). No change was found in the rate of wound infection (4 vs 
11 patients; P = 1.00). Length of stay, readmissions within 30 days of discharge and 
reoperations were all significantly increased in patients with POI (Table 3). Length of 
stay was significantly associated with POI when corrected for other complications, 
ASA-grade, rectal surgery and duration of surgery (OR 1.51 CI 1.34-1.70 P < 0.001). 
In addition, patients with POI as only complication were on average admitted 4 days 
longer than patients with an uncomplicated recovery. The length of stay of patients 
without complications was median 4 days (IQR 3 - 6 days) and was for only-POI patients 
median 8 days (IQR 7 - 12 days, P < 0.001). Furthermore, 5% (2/38) of patients with only 
POI underwent additional surgical laparoscopy because of clinical deterioration with 
no new findings, and 13% (5/38) of only POI patients was readmitted to the hospital 
within 30 days after discharge.
3.4.5. Laparoscopic and open surgery
It is recognized that the surgical approach, open or laparoscopic surgery, has effect 
on surgical outcomes. In this study, both open and laparoscopic cases were included. 
Therefore, additional analyses were performed on the total study population. In 
patients undergoing open surgery 30% (34/112) developed POI. In the group undergoing 
laparoscopic procedure 21% (32/153) developed POI (P = 0.079). Length of stay was 
6 days longer in the POI group compared to the non-POI group, and when stratified 
for open and laparoscopic approach, patients were admitted 5 days longer when they 
received open surgery and developed POI (6 days IQR 5 - 7 no POI; vs 11 days IQR 8 – 15 
POI) and 4 days longer when patients had laparoscopic surgery and developed POI (4 




There was no difference in open or laparoscopic surgery in patients with POI and other 
complications, i.e. patients who had an open procedure and had POI did not develop 
more complications than laparoscopic operated patients.
In addition, patients without complications were admitted 1 day longer when they 
received open surgery compared to laparoscopic surgery (5 days IQR 5 - 7 open surgery; 
vs 4 days IQR 3 - 5 laparoscopic surgery). Moreover, patients were also admitted 1 day 
longer when they had POI as only complication and had open surgery than laparoscopic 
surgery (9 days IQR 8 - 14 open surgery; vs 8 days IQR 7 - 12 laparoscopic surgery).
Next, there was a clear difference in level of inflammation between patients that had 
laparoscopic surgery and open surgery. Inflammation was significantly lower in patients 
that had a laparoscopic procedure 4 hours, 24 hours and 48 hours after surgery for 
IL-6, IL-8 and IL-10. Of note, this significant difference was already apparent before 
surgery (0 hours). For CRP inflammation was only lower on POD1 for laparoscopic 
surgery compared to open surgery (Table S3 supplementary data). Interestingly, as 
demonstrated earlier, while IL-6 levels are significantly higher in patients with only POI 
compared to patients without complications 24 and 48 hours after surgery and similar 
higher levels of IL-6 in laparoscopic versus open surgery, in case of stratifying the POI 
patients and the patients without complications for laparoscopic and open surgery, 
results are not significant. For Il-6, between laparoscopic and open surgery, levels 
increase. CRP levels are more consistent; levels of CRP do not differ much between 
open or laparoscopic surgery, and significant higher levels of CRP remain in POI patients 
compared to no complications.
3.5. DISCUSSION
We report here that patients having colorectal surgery resulting in POI as a complication, 
had a higher level of circulating inflammatory biomarkers, an increased length of 
stay, a decreased quality of life and more healthcare costs compared to patients with 
uncomplicated recovery. This study provides novel information because data was 
analyzed in patients with POI as a unique complication, where most studies allow for 
a mix of postoperative events possibly leading to bias. Moreover, these results were 
consistent in the total study population in which patients with other complications 
were included. Patients with POI were more at risk to develop other and more severe 
complications. The results of this study regarding the rise of inflammatory markers are 
in agreement with those of animal studies showing that increased levels of inflammatory 
cytokines and chemokines are detectable systemically next to a localized inflammation 
in the gut following its manipulation during surgery.5, 27, 28 Furthermore, we demonstrate 
that POI is a strong driving factor in upregulating the inflammatory response after 
surgery, irrespective of the surgical open or laparoscopic approach.
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Recently, a study of Boersema et al26 showed an association between systemic cytokines 
and postoperative complications in patients, and IL-6, also elevated in our study, had 
the best diagnostic value in predicting infectious complications. Of note, patients with 
POI had higher levels of IL-6 and CRP in that study, however not significantly because of 
a small sample size. We observed elevated levels of IL-10 in our study as well, and those 
were similarly reported by others to occur in the early phase of POI in patients, being 
significantly increased in patients with longer recovery from POI in abdominal surgery.29 
Remarkably, in animal models IL-1β has been suggested to play an important role in POI 
pathology,10 however systemic levels of IL-1β were very low and no differences were 
shown between patients with and without POI, which was also reported by Boersema 
and colleagues.26
Another important finding in this study is the confirmation of data from experimental 
studies that inflammation is elevated early after manipulation of the intestine. An 
increased inflammatory response early after surgery may be causal for development 
of POI.11 The analysis of patients with POI as only complication showing increased 
inflammation supports this, as soon as 24 hours after onset of surgery CRP and IL-6 have 
risen significantly. Besides, in the total study population, co-existing complications could 
also contribute, many of these complications present later in the postoperative period. 
For instance, the interval between surgery and anastomotic leakage was median 7 days 
in patients with POI that developed anastomotic leakage in this study, which is in line 
with earlier studies where a median interval of 6-12 days was reported for anastomotic 
leakage and 8 days for all infectious complications.30-33 Importantly, POI is associated 
with anastomotic leakage, although the causal relation of anastomotic leakage and 
POI is to be determined.5 Irrespective, reducing early inflammatory activation could 
be considered to reduce both POI and anastomotic leakage in patients at risk. From 
another point of view, higher cytokine levels, regardless of its cause, indicate poorer 
outcomes: Patients develop POI and are at significant risk of developing other adverse 
outcomes. This was shown in this study with POI patients having another complication 
in 42%, while non-POI patients developed a complication in 28%, with an odds ratio of 
2.31. Therefore, POI may be an early marker of complications or maybe even a marker 
of poor outcomes in the setting of other complications.
In animal studies, interventions have been explored aiming to reduce the early 
inflammatory responses that lie at the basis of POI. For instance, prucalopride, a5-Ht4 
receptor agonist, and vagus nerve stimulation, either electrical or via lipid-enriched 
nutrition inhibits inflammation in an early stage and can prevent experimental POI.18, 34, 
35 Interestingly, two recent clinical pilot studies by Stakenborg et al showed promising 
results in patients. Preoperative administration of prucolapride resulted in decreased 
local IL-6 and IL-8 expression and improved clinical recovery in a small cohort of 
patients.18 36 In another pilot study in which abdominal vagus nerve stimulation was 




stimulation could reduce levels of cytokines induced by ex vivo lipopolysaccharide (LPS) 
stimulation of whole blood. This suggests a systemic modulatory effect on immune cells, 
and there is great potential for future studies in this field. However, it remains uncertain 
whether the interventions that were effective in animal studies have an effect on POI 
clinically, especially since enteral nutrition was not able to reduce POI in a clinical trial 
performed by our group.13
Many different risk factors for POI have been described.37-39 In this study ASA grade and 
duration of surgery were independent risk factors. It is notable that patients with POI as 
only complication did smoke and used alcohol more often. Furthermore, these patients 
had more open surgery, more intraoperative blood loss and received a colostomy more 
often. Of note, some of the patients that reported lower levels of QoL preoperatively, 
in particularly physical functioning, developed POI as only complication. Patients with 
POI experienced reduced QoL in different modalities. This effect was not limited to the 
direct postoperative period, but remained evident three and six months after surgery, 
emphasizing the long-term impact of the burden of POI in patients. The current results 
are in line with a prospective study where the impact of postoperative complications 
after colorectal cancer surgery on long-term QoL was investigated,6 though specific 
selection of patients with POI had not yet been applied. Besides, POI was associated 
with additional complications, which evidently affects the QoL of these patients. In 
the present study, QoL was still reduced after three months in the selected group 
of patients with POI as unique complication. This is remarkable, and shows that POI 
which usually resolves in a couple of days in the hospital and is often considered a 
minor complication has great impact on patients’ lives, even months after discharge. 
It is likely that in the total population anastomotic leakage and pneumonia contribute 
to an increased length of stay and costs, and a reduced QoL in patients with POI even 
6 months after surgery. Since patients with POI are at significant risk of developing 
other complications, POI leaves its mark on society. Furthermore, an earlier study 
showed a relationship between POI and other complications and a higher mortality 
rate in patients with POI and additional complications.4 The latter is one of the few 
studies that analyzed POI as unique complication, however only reports on 30 day-
mortality for the POI only group, which was equal to patients without POI (1%). In 
the past, few studies have calculated costs for patients with POI, and some did not 
report if patients had other complications as well. A retrospective cohort study of Iyer 
et al in the United States showed a mean difference of $8000 for patients with POI 
vs without POI in hospitalization costs.3 Another retrospective study of Asgeirsson et 
al40 of 184 patients that underwent a colectomy showed similar results (US $16612 
vs $8316), obtaining their cost data through a hospital accounting system. In a more 
recent study, POI patients were found to be more expensive even after adjustment for 
major complications and length of stay.41 In the current study data were prospectively 
collected and all the relevant costs from the broadest perspective were included in an 
economic evaluation, thereby measuring the impact on society.23 Interestingly, data on 
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complications in colorectal surgery showed that 31% of the total hospital costs were 
spent on complications.7 Conversely, we show that patients with POI have a higher 
chance of developing other complications which is accompanied with a 9% rise in costs 
and decline in Global QoL. The data from our study emphasize the societal impact (both 
QoL and costs) of POI and the necessity to keep searching for applicable therapeutics 
and reduce costs.42
The strengths of this study are that data were prospectively collected as part of a RCT 
with a clear definition of POI as primary outcome, a high response rate regarding cost 
and QoL data and almost complete data on inflammatory markers. Analyses were done 
on both a selected group of patients that only developed POI, as well as the whole 
study population, representing the general population undergoing colorectal surgery 
to substantiate the results. This study has also limitations. First, systemic cytokine levels 
were determined, whereas cytokine levels locally in the bowel wall may be a better 
reflection of a local inflammatory response associated with POI. Second, costs and QoL 
were assessed by self-reported questionnaires which may result in recall bias, although 
the overall completion rate was 88%. The cost elements for all participating centers (of 
which some are located in Denmark) reflect the reference prices from the Netherlands 
which may have influenced the total cost estimates.
In conclusion, POI has a significant negative impact on quality of life, increases length of 
stay and is associated with a higher overall complication rate. The differences between 
the selected group of patients with POI as unique complication (n=38) and the total 
group of patients with POI who developed other complications as well (n=66) are 
relatively small, demonstrating the impact of POI and the large contribution of POI in 
postoperative inflammation, length of stay, costs and QoL in the general population 
of patients undergoing colorectal surgery. This study confirms the association of POI 
with inflammation and this supports that therapeutic strategies need to be developed 
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SUPPLEMENTARY INFORMATION
Table S1. Inflammatory markers in patients with POI compared to patients without complications




Table S3. Inflammatory markers in patients that received laparoscopic surgery compared to 
open surgery
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Background: Postoperative ileus (POI) and anastomotic leakage (AL) following colorectal 
surgery severely increase healthcare costs and decrease quality of life. This study 
evaluates the effects of reducing POI and AL via perioperative gum chewing compared 
to placebo (control) on in-hospital costs, health-related quality of life (HRQoL), and 
assesses cost-effectiveness.
Methods: In patients undergoing elective, open colorectal surgery, changes in HRQoL 
were assessed using EORTC-QLQ-C30 questionnaires and costs were estimated from a 
hospital perspective. Incremental cost-effectiveness ratios were estimated.
Results: In 112 patients, mean costs for ward stay were significantly lower in the gum 
chewing group when compared to control (€3522 (95% CI €3034-€4010) versus €4893 
(95% CI €3843-€5942), respectively, p = 0.020). No differences were observed in mean 
overall in-hospital costs, or in mean change in any of the HRQoL scores or utilities. Gum 
chewing was dominant (less costly and more effective) compared to the control in more 
than 50% of the simulations for both POI and AL.
Conclusion: Reducing POI and AL via gum chewing reduced costs for ward stay, but did not 
affect overall in-hospital costs, HRQoL, or mapped utilities. More studies with adequate 
sample sizes using validated questionnaires at standardized time points are needed.
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4.1. INTRODUCTION
Postoperative outcomes following colorectal surgery have markedly improved since the 
implementation of fast-track protocols 1. However, the incidence of severe complications 
including anastomotic leakage (AL) (up to 19%) and postoperative ileus (POI) (up to 45%) 
remains substantial 1-4. Postoperative complications strongly increase healthcare costs 
and negatively impact both short and long term quality of life (QoL) 5-12.
In a recent randomized trial, perioperative gum chewing significantly reduced POI 
(14/52 patients versus 29/60 patients) and AL (2/52 patients versus 8/60 patients) 
when compared to placebo 4. However, given the current trend of rising healthcare 
expenditures, new interventions cannot be implemented in routine care based on 
clinical efficacy alone. Economic evaluations are warranted to determine the value for 
money of an intervention 13. While perioperative gum chewing had a clear beneficial 
effect on clinical outcomes 4, the effects on in-hospital costs and QoL are unknown.
This study evaluates the effects of reducing POI and AL via perioperative gum chewing 
compared to control on in-hospital costs and health-related quality of life (HRQoL), and 
estimates cost-effectiveness in patients undergoing colorectal cancer surgery.
4.2. MATERIALS AND METHODS
This is a substudy from a previous multicenter, single-blind, randomized controlled trial 
in two large Dutch tertiary referral hospitals (Catharina Hospital and Orbis Medical 
Center) 4. The original trial was conducted according to the Declaration of Helsinki, 
and was approved by the local Medical Ethics Committee on November 19th, 2008 (No 
08-T-70). All patients signed informed consent prior to participation.
4.2.1. Patient population
Patients were included in the original trial as described elsewhere 4. Briefly, patients 
were eligible for inclusion if aged 18 or older and undergoing elective, open colorectal 
surgery. Patients were excluded in case of the presence of peritoneal carcinomatosis, 
inflammatory bowel disease, a history of gastric or esophageal surgery, a disturbance 
of acetylcholine metabolism owing to neurological disease or depression, pre-existing 
ileostoma, allergy to mint, or if using agents influencing gut motility (including opioids) 
or acetylcholine metabolism.
4.2.2. Interventions
Patients were randomly allocated to the intervention or placebo group. Patients in 
the intervention group started chewing gum at least three hours prior to the start 
of surgery, and again three hours after end of surgery. Patients in the control group 




instructed to not chew gum. Both the intervention and control were discontinued 
when patients started an oral diet 4. Further details on the intervention and control 
are described in the original trial report 4.
4.2.3. Clinical outcomes
The primary outcome of the original study was length of stay. Secondary outcome 
measures included POI and AL 14.
4.2.4. Health-related quality of life and utilities
Health-related quality of life was a secondary endpoint in the original trial 4 and was 
assessed preoperatively and postoperatively using the European Organization for 
Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-
C30 version 3.0) 15. The time point for completion of the postoperative QLQ-C30 
questionnaire was not standardized. Missing data were imputed according to the EORTC 
guidelines 15.
Utilities are preference weights for different health states in which more preferred 
health states receive more weight. Utility scores range between 0 (death) and 1 
(perfect health). Mapping was done to compute utility scores from HRQoL-scores 16. 
The differences between the pre- and post-operative HRQoL and utility scores were 
reported as changes in mean.
4.2.5. Costs
Costs were calculated from the hospital perspective. In-hospital costs were 
determined by retrospectively extracting financial data from the electronic patient 
registration system. Additionally, costs for readmission within 1 year after surgery 
due to complications stemming from the primary operation were included. Costs 
were estimated using a bottom-up approach. Only the standardized unit costs of the 
Catharina Hospital were available; consequently these were also used for units of 
care from the Orbis Medical Centre. Costs were categorized into fees for the primary 
operation, pathology, laboratory tests, radiological examinations, intramural consults, 
therapeutic interventions under local anesthesia, re-operations, and admission costs for 
staying in the surgical ward and/or intensive care unit. Monetary units are expressed 
in Euros (€) and were indexed for the year 2011, as this was the year in which most 
patients were included in the original trial 4
4.2.6. Cost-effectiveness evaluation
The implementation of a new treatment depends on the maximum amount of money 
that society is willing to pay for a gain in effectiveness, which is termed the “threshold” 
or “ceiling-ratio”. The gain in effectiveness is most commonly expressed in quality-
adjusted life years (QALYs) 17. However, it was considered inappropriate to estimate 
QALYs from the available data, since the time point for postoperative QoL assessment 
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was not standardized, and the required utility scores needed to be mapped from the 
EORTC QLQ-C30 scores. Instead, cost-effectiveness was assessed using the two clinical 
outcomes that were significantly reduced by perioperative gum chewing in the original 
trial (POI and AL) 4. A cost-effectiveness analysis was performed by determining the 
incremental cost-effectiveness ratio (ICER) of gum chewing in comparison with the 
control. ICERs were calculated by dividing the incremental costs by the incremental 
effects; the sample uncertainty concerning the ICERs was quantified by conducting 
5000 bootstrapping replications. The ICERs are presented on a cost-effectiveness plane, 
which is divided into four quadrants. When the intervention is more effective and less 
costly than the comparator, the ICERs lie in the southeast quadrant and the intervention 
is considered dominant. Conversely, when the intervention is less effective and more 
costly, the ICERs lie in the northwest quadrant and the intervention is considered 
inferior. When the intervention is more costly and yet more effective, the ICERs lie 
in the northeast quadrant and when intervention is less costly and less effective, the 
ICERs lie in the southwest quadrant. A treatment is cost-effective when it is dominant.
As there is uncertainty surrounding the threshold per avoided incident of POI or AL, 
cost-effectiveness acceptability curves (CEAC) were used to present the results of the 
bootstrapping. A CEAC is a graphic representation of the uncertainty in differences in 
cost and effect between the two groups, showing the probability of an intervention 
being cost-effective for a wide range of threshold values.
4.3. STATISTICAL ANALYSIS
Normally distributed data are presented as means (standard deviation) and were tested 
using the unpaired t-test, while non-parametric data are presented as median [range] 
and were tested using the Mann-Whitney U test. Categorical variables were tested with 
the Χ2 test. Cost data are presented as means, medians and 95% confidence intervals, 
as is recommended for cost-analysis studies 18. Cost means are compared using the 
unpaired t-test.
As perioperative gum chewing was hypothesized to affect only the postoperative course 
and not the type of operation and subsequent pathology analysis of the resected tissue, 
a sensitivity analysis was performed in which only postoperative costs were included.
Furthermore, as the original study was not powered to detect changes in HRQoL or 
costs, a post hoc power analysis was performed using an α equal to 0.05 to assess 
the statistical power of the current analysis. The statistical power (mean ± S.D.) of 
preoperative, postoperative, and delta change HRQOL scores were 0.29 ± 0.26, 0.12 
± 0.2 and 0.07 ± 0.06 respectively. The statistical power analysis for total costs, total 







A total of 120 patients were included in the original study, of which 58 patients were 
randomized to the intervention group and 62 patients to the control group. Groups were 
similar at baseline with regard to demographic variables, co-morbidities, and operative details 
(Table 1, adapted with permission from Heijkant et al. 4). Eight patients were excluded after 
randomization due to technical reasons4 and were not included in any analysis in this paper.
Table 1. Baseline characteristics
 Gum Chewing Control
(N=58) (N=62)
Age (years)a 66 ± 9 67 ± 11 0.864*
Sex ratio(M:F) 38 : 20 46 : 16 0.300
Height (cm)a 173 ± 9 172 ± 9 0.906*
Weight(kg)a 80 ± 17 77 ± 11 0.267*
BMI(kg/m2)a 27 ± 5 26 ±  4 0.283*
ASA fitness grade
   I 8 (14) 10 (16)
   II 44 (76) 45 (73)
   III 6 (10) 7 (11)
Previous abdominal surgery 14 (24) 17 (27) 0.820
Diabetes mellitus 10 (17) 11 (18) 0.898
Smoking 6 (10) 10 (16) 0.799
Alcohol use 18 (31) 24 (39) 0.258
SSRI use 1 (2) 1 (2) 0.925
Duration of surgery(min)b 135 [65-491] 142 [65-452] 0.584**
Blood lossb 300 [0-2000] 300 [0-4000] 0.896**
Colostomy required 29 (50) 29 (47) 0.855
Type of operation 1.000
   Right hemicolectomy 16 (28) 17 (27)
   Left colectomy 18 (31) 20 (32)
   Rectal resection 22 (38) 23 (37)
   Other 2 (3) 2 (3)
Values are presented as number (%) or as amean(S.D) or bmedian [range].  All 
tests are χ2 test, except * unpaired t-test and ** Mann-Whitney U test. ASA, 
American society of Anesthesiologists; SSRI, selective serotonin reuptake 
inhibitor. Adapted with permission from Heijkant et al.
P-value
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As noted in the original study report, incidence of POI was significantly lower in the 
gum chewing group compared to the control group (14/52 patients versus 29/60 
patients, respectively, p = 0.02).4 Furthermore, fewer patients in the gum chewing 
group experienced AL, in comparison with the control group (2/52 patients versus 
8/60 patients, respectively, p = 0.03) 4.
4.4.3. Health-related quality of life and utilities
Out of 112 patients, 95 patients completed the preoperative baseline questionnaire and 
69 patients completed the postoperative questionnaire. A total of 66 patients completed 
both the pre- and postoperative questionnaires. The time point of completing the 
postoperative questionnaire was similar in both groups: median postoperative day 6 
(range 2-39) in the gum chewing group and median postoperative day 8 (range 2-70) 
in the control group (p = 0.19). On average, 0.31 out of 30 questions were imputed 
per questionnaire. Pre- and postoperative HRQoL and mapped utility scores, and the 
change in scores between the two time points, are summarized in Table 2. The pre- 
and postoperative emotional functioning scale showed a significantly higher mean 
score in the gum chewing group (p < 0.01 and p = 0.02, respectively). The preoperative 
fatigue scale showed a significantly lower score in the gum chewing group (p = 0.03). 
Preoperatively, patients in the control group had significantly more appetite loss in 
comparison with the patients in the gum chewing group (p = 0.02). No other significant 
differences were seen between groups.
At baseline, patients in the gum chewing group showed a higher score in utilities 
(p = 0.01); however postoperative utilities and change in utilities between the two time 
points were similar between groups (p = 0.43 and p = 0.53, respectively).
4.4.4. Costs
In-hospital costs are presented in Table 3. Total costs for admission (p = 0.71), total costs 
for readmission (p = 0.78), and total costs for admission and readmission combined 
(p = 0.85) were not statistically different between groups. However, mean costs for 
ward stay were lower in the gum chewing group when compared to the control group 
(p = 0.02). In the sensitivity analysis, which excluded costs for primary operation and 
pathology analysis, there were no differences in postoperative admission costs, or in 
the combined postoperative admission and readmission costs (p = 0.67 and p = 0.82, 
respectively).
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Table 4. Incremental costs, effects and ICERs of the outcomes of the study
Incremental costs(€) Incremental effects ICER
Postoperative ileus -507 0.21 -2414
Anastomotic Leakage -507 0.06 -8450
ICER, incremental cost effectiveness ratio
Table 5. Sensitivity analysis of cost-effectiveness analysis
Outcome Dominance Inferiority
Postoperative admission costs
Anastomotic leakage 65% 8%
Postoperative ileus 67% 1%
Postoperative admission + readmission costs
Anastomotic leakage 57% 10%
Postoperative ileus 61% 1%
Probability of gum chewing being dominant or inferior compared to placebo 
when excluding costs for primary operation and pathology.
4.4.5. Cost-effectiveness analysis
Incremental costs, effects, and ICERs relating POI and AL were estimated using the total 
admission and readmission costs combined. The incremental mean costs divided by 
the incremental mean effects resulted in an ICER of -8,450 per AL and -2,414 per POI 
(Table 4). Both ICERs were negative, indicating that the gum chewing group dominated 
the control group due to lesser costs and positive effect (i.e. reduction in POI or AL).
The uncertainty analyses of the ICERs representing 5000 bootstrap replications are 
presented in the cost-effectiveness plane (Figure 1). For AL, 56% of the bootstrapped 
replications were located in the southeast quadrant, indicating the dominance of gum 
chewing (i.e positive effect at lesser costs), while 9% of the bootstrapped replications 
were located in the northwest quadrant, indicating inferiority (Figure 1a). For POI, 
the cost-effectiveness plane shows that 59% of the replications were located in the 
southeast quadrant, indicating dominance, while 1% of the replications were located 
in the northwest quadrant, indicating inferiority (Figure 1b).
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(a) 
(b) 
Figure 1. (a) Cost-effectiveness of gum chewing versus placebo expressing costs per avoided 
incident of anastomotic leakage. (b) Cost-effectiveness plane of gum chewing versus placebo 
expressing costs per avoided incident of postoperative ileus
Figure 2 represents the CEAC for AL and POI. The probability of gum chewing being 
cost-effective in reducing POI and AL is >50% regardless of the applied threshold 
for willingness to pay. The sensitivity analyses for the cost-effectiveness analyses 
including only the postoperative costs are summarized in Table 5. Excluding costs 
for the primary operation and pathology analysis increased the probability of 




Figure 2. cost-effectiveness acceptability curves of postoperative ileus (POI) and anastomotic leakage (AL)
Figure 3. Sensitivity analysis of cost-effectiveness acceptability curves for postoperative admis-
sion costs (AL, anastomotic leakage; POI, postoperative ileus)
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Figure 4. Sensitivity analysis of cost-effectiveness acceptability curves for postoperative admis-
sion + readmission costs (AL, anastomotic leakage; POI, postoperative ileus)
4.5. DISCUSSION
This study aimed to estimate the cost-effectiveness of perioperative gum chewing in 
colorectal cancer patients and to assess the effects on HRQoL, utilities, and in-hospital 
costs. Based on our data, gum chewing may be cost-effective in reducing POI, and to 
a lesser extent in reducing AL, while no clear benefit of gum chewing was observed 
on HRQoL, mapped utilities, and overall in-hospital costs. However, gum chewing was 
associated with a significant reduction in costs for ward stay.
The probability of gum chewing being dominant over the control was >50% for both 
POI and AL, regardless of the threshold value. In a recent randomized controlled trial 
comparing postoperative gum chewing (starting on day 1 after surgery) with standard 
care, Atkinson et al. found no differences in net monetary benefit between groups and 
concluded that gum chewing is unlikely to be cost-effective 19. However, comparing the 
study by Atkinson and colleagues with our findings is inappropriate due to important 
differences between studies regarding (A) timing of gum chewing (postoperative 19 
versus perioperative 4), (B) clinical outcomes (no benefits of gum chewing 19 versus a 
reduction of POI and AL 4), (C) cost perspective (societal 19 versus hospital 4), and (D) 
measurement of effects in cost-effectiveness analysis (QALY 19 versus POI/AL 4). Further 




Perioperative gum chewing reduced costs for ward stay, but did not reduce overall 
costs. We hypothesize that the reduction in ward stay costs in the gum chewing group 
is directly linked to the reduction of POI and therefore shorter length of stay 4. Both 
POI and AL are known to severely increase healthcare costs 5-7, as was visible in our 
data set when comparing total costs between patients with and without POI or AL 
(data not shown). As gum chewing conferred a reduction of both POI and AL 4, the lack 
of a significant difference between the groups in mean overall costs may be explained 
by the fact that the original study 4 was not powered to detect differences in costs. In 
addition, as opposed to cost-effectiveness analyses, the crude comparison between 
groups using p-values may not be the optimal method for detecting any cost-reducing 
effects of an intervention 18.
Surgery for colorectal cancer has been shown to improve quality of life 3 months 
after surgery 20. Conversely, in our cohort, mean HRQoL scores and mapped utilities 
deteriorated in both groups after surgery. This may be explained by the fact that most 
patients completed the postoperative questionnaire within 10 days after surgery while 
still recovering from the surgical trauma regardless of complications. In general, QoL 
may not return to preoperative levels within the first 3 weeks after surgery even in the 
absence of complications 21, while postoperative complications can have both short- and 
long-term negative effects on QoL 9-12. Reducing postoperative complications may limit 
the decrease in QoL shortly after surgery; however this could not be demonstrated in 
our data. Future studies with repeated QoL assessments using validated questionnaires 
at standardized time points are needed to provide more insight into the effects on 
postoperative QoL by interventions that reduce complications.
Several limitations are present in the current study. As noted, the original trial 4 was 
not powered to detect differences in in-hospital costs or quality of life, but rather 
on clinical outcomes. Moreover, there was a significant number of missing QLQ-C30 
questionnaires and consequently the results were based on a limited sample size. 
The estimation of QALYs was inappropriate given the non-standardized time point for 
postoperative QoL assessment and the necessity of mapping the HRQoL scores to the 
required utility scores. A cost-utility analysis, as is recommended for current economic 
evaluation studies, could therefore not be performed. Furthermore, the obtained costs 
were from a hospital perspective only and productivity costs were not included. Lastly, 
this study was conducted as a trial-based economic evaluation, which may limit the 
generalizability of the results 22.
Overall, our data suggests that reducing POI and AL via perioperative gum chewing 
reduces costs for ward stay, but does not reduce overall in-hospital costs or confer a 
beneficial effect on HRQoL or mapped utilities. Although the CEAC curves suggest that 
gum chewing may be cost-effective for a wide range of threshold values, we cannot 
conclude with certainty that gum chewing is cost-effective in reducing POI or AL due to 
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the limitations of our data. We recommend future studies with appropriate sample sizes 
to incorporate repeated assessments of QoL and utilities using validated questionnaires 
(e.g. EORTC QLQ C-30, EQ-5D-5L) at standardized time points. In addition, the use of 
a productivity cost questionnaire and medical cost questionnaire is recommended in 
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Aims: The objective of this (trial-based) economic evaluation was to assess, from a 
societal perspective, the cost- effectiveness of perioperative enteral nutrition compared 
with standard care in patients undergoing colorectal surgery.
Methods: Alongside the SANICS II randomized controlled trial, global quality of life, 
utilities (measured by EQ-5D-5L), healthcare costs, production losses and patient and 
family costs were assessed at baseline, 3 months and 6 months. Incremental cost-
effectiveness ratios (ICERs) (i.e. cost per increased global quality of life score or quality-
adjusted life year (QALY) gained) and cost-effectiveness acceptability curves were 
visualized.
Results: In total, 265 patients were included in the original trial (n=132 in the 
perioperative enteral nutrition group and n=133 in the standard care group). At 6 
months, global quality of life (83 versus 83, p=0.357) did not differ significantly between 
the groups. The mean total societal costs for the intervention and standard care groups 
were €14,673 and €11,974 respectively but did not reach the statistical significance 
(p=0.109). The intervention resulted in an ICER of -€6276 per point increase in the 
global quality of life score. The gain in QALY was marginal (0.003) with an additional 
cost of €2,941 and the ICUR (Incremental cost utility ratio) was estimated at €980,333.
Limitations: The cost elements for all the participating centers reflect the reference 
prices from the Netherlands. Patient-reported questionnaires may have resulted in 
recall bias. Sample size was limited by exclusion of patients who did not complete 
questionnaires at least at two time points. A power analysis based on costs and health-
related quality of life (HRQoL) was not performed. The economic impact could not be 
analyzed at 1 month postoperatively where the effects could potentially be higher.
Conclusions: This study suggests that perioperative nutrition is not beneficial for the 
patients in terms of quality of life and is not cost effective.
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5.1. INTRODUCTION
Postoperative outcomes following colorectal surgery have tremendously improved as 
a result of the implementation of fast-track protocols.1 Despite these beneficial results, 
anastomotic leakage (AL) and postoperative ileus (POI) are still important determinants 
of postoperative morbidity (1- 19% and 27-48% respectively).1-4 Postoperative 
complications strongly increase healthcare costs and can negatively impact both short- 
and long-term quality of life (QoL).5-10
In previous clinical studies, POI was reduced (from 35% to 16%) when enteral nutrition 
was started very early after rectal surgery.11 A recent randomized controlled trial (SANICS 
II trial) was conducted to assess the clinical and economic effects of perioperative lipid-
enriched enteral nutrition versus standard care following colorectal surgery. 12 This trial 
demonstrated that perioperative enteral nutrition (PEN) did not significantly reduce 
postoperative complications.12 Although there is no demonstrated advantage of PEN 
in terms of postoperative complications, it is important to study the impact of the 
intervention on societal costs and health-related quality of life which (HRQoL) could 
potentially be different. Furthermore, it is important to investigate the (societal) costs 
of such an intervention, that in some specific surgical patients with higher inflammatory 
response, could be more beneficial. Economic considerations are nowadays increasingly 
important in our healthcare system to help decision makers to efficiently allocate 
resources. This study is therefore a report on the total societal costs, quality of life 
and on the cost-effectiveness of the intervention perioperative lipid-enriched enteral 
nutrition versus standard care following colorectal surgery.
The aim of this study was thus to compare, from a societal perspective, the cost-
effectiveness (i.e. cost per point increase in global quality of life score, measured using 
EORTC QLQ-C30 questionnaires) and cost-utility (i.e. cost per quality-adjusted life years 
[QALY] gained) of the PEN with standard care (control) in patients undergoing colorectal 
surgery over a period of 6 months.
5.2. METHODS
5.2.1. Design
This trial-based economic evaluation is embedded in a randomized controlled trial in 
which the clinical effectiveness of PEN was previously assessed. 12 The original study 
was a multicentre double-blind, randomized controlled trial that was conducted in 
three large Dutch hospitals and two Danish hospitals. The trial was designed to compare 
lipid-rich nutrition administrated just before, during and after colorectal resection to 
standard care (no nutrition). The original study was approved by the Medical Ethics 
Committee of the Catharina Hospital (Eindhoven, The Netherlands). The principles of 




registered with ClinicalTrials.gov (number NCT02175979) and trialregister.nl (number 
NTR4670). All patients provided written informed consent. Further details regarding 
the trial and the clinical results can be found elsewhere. 12
The economic evaluation was performed according the Dutch guideline for economic 
evaluation13 and the Consolidated Health Economic Evaluation Reporting Standards.14
5.2.2. Participants and setting
All patients recruited to the SANICS II trial described earlier were considered for 
inclusion in the current study. Briefly, patients were eligible for inclusion if aged 
18 or older and undergoing elective segmental colorectal resection with primary 
anastomosis. The exclusion criteria were previous gastric or oesophageal resection, 
peritoneal metastases, an ileostomy, and the use of glucocorticosteroids or medication 
that disrupted acetylcholine metabolism (e.g., selective serotonin reuptake inhibitors 
or anticonvulsants). The patients were not identified to be malnourished and were 
randomly assigned to the intervention or standard care group and stratification was 
applied to ensure an equal distribution between colonic and rectal surgery and between 
laparoscopic and open procedures.
5.2.3. Interventions
Detailed information on the intervention and its composition is found in the original 
article.12 All the patients received a self-migrating naso-jejunal tube and were connected 
to a tubing system. The tubing system was opaque and bifurcated into two branches. 
One branch was connected to the tube in the patient and the other branch was occluded 
at the bifurcation by the manufacturer. For patients in the intervention group, the 
tubing system was open towards the patient and closed towards the blinded container.
Conversely, for patients allocated to the standard care group, the tubing system was 
closed towards the patient and open towards the blinded container. Consequently, 
only patients in the intervention group received the lipid enriched nutrition. Patients 
received continuous lipid enriched enteral tube feeding from 3 hours before until 6 
hours after surgery. This special nutrition (Nutricia Research, Utrecht, Netherlands) 
was composed of chemicals, minerals and vitamins. Patients allotted to the standard 
care group did not receive PEN and were treated to ERAS (Enhanced Recovery After 
Surgery) guidelines.
5.2.4. Economic evaluation
A cost-effectiveness analysis and cost utility analysis were performed in this study. 
Self-reported questionnaires were administrated to all patients at baseline, 3 months 
and 6 months.
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The outcome of the cost-effectiveness analysis (CEA) was global quality of life retrieved 
from the European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire (EORTC QLQ-C30) questionnaires. Six-month mean values were calculated 
using T0, T1 and T2 scores. The EORTC QLQ-C30 is a cancer specific questionnaire that 
includes the function domains (physical, emotional, social, role and cognitive), eight 
symptoms (fatigue, pain, nausea/vomiting, constipation, diarrhea, insomnia, dyspnea 
and appetite loss) as well as global health/quality of life and financial impact. Each 
dimension was scored on a four point scale from “not at all” to “very much” for most 
items. Raw scores are converted to a 0-100 scales with higher scores reflecting higher 
levels of function and higher level of symptom burden. Patients with non-malignant 
nature of the disease were excluded from this cost-effectiveness analysis.
The outcome of the cost-utility analysis (CUA) was QALY as it is the preferred and 
the most common outcome in economic evaluation. QALYs were calculated by means 
of the “area under the curve” method, in which the time in a certain health state 
was multiplied by the utility of this health state.15 It was measured with EQ-5D-5L 
questionnaire which is the international standard for utility measurement16 and consists 
of five dimensional Euroqol (EQ-5D-5L) comprising of mobility, selfcare, usual activities, 
pain/discomfort and anxiety/depression. Each dimension was scored on five-point 
scale which represented ‘no problems’, ‘slight problems’, ‘moderate problems’, ‘severe 
problems’, and ‘extreme problems’. Utilities were derived from EQ-5D-5L using Dutch 
tariffs.16 The five dimensions can be summed into a health state. Utility values were 
calculated for these health states, using preferences elicited from a general population, 
the so called Dutch algorithm.16
5.2.5. Costs
Cost data were collected at 3 months and 6 months. Costs were calculated from a 
societal perspective meaning that all costs and (monetary) benefits were included 
regardless of who pays the costs or who gain the benefits. The iMTA Medical 
consumption questionnaire (iMCQ) was used to measure the healthcare utilization 
and the iMTA productivity cost questionnaire (iPCQ)17 was used to measure the costs 
due to productivity losses in two domains related to 1) paid work due to absenteeism 
and presenteeism, and 2) unpaid work.17 The recall period for the iMCQ is 3 months 
and for the iPCQ is 4 weeks.
Costs were divided into three categories: healthcare sector costs, costs for patient 
and family and productivity costs. Healthcare costs consisted of medication costs, 
consultations with healthcare professionals, use of diagnostic methods, frequency of 
inpatient stay and outpatient treatment. The calculation of healthcare costs was based 
on identified health services consumed by the patient and was multiplied with their 
corresponding unit prices. Total costs were estimated by summing individual services. 




valuation of the healthcare costs.13 All medication costs were derived from the website 
with official listing of drugs with prices: www.medicijnkosten.nl. Medication costs were 
based on the price per dosage of the drug in the Netherlands. In case of uncertainty, 
a lowest cost price was used. Medications without a specific name were omitted (for 
example, when patient mentions antibiotics or “medicine for stomach protection”). 
Patient and family costs included the use of formal (paid care) and informal care. The 
costs for unpaid care were valued using the proxy good method, which values the 
time spent on informal care at the labor market price of a close market substitute. 
Productivity costs included productivity losses due to absence from work and were 
valued using friction cost method as recommended by Dutch guidelines.13 The friction 
cost method takes into account production losses confined to the period needed to 
replace the sick employee (85 days).18. All costs were indexed for the year 2017. The 
study follow-up was 6 months and therefore no discounting was performed (for either 
costs or effects).
5.3. ANALYSES
Analyses were conducted using IBM SPSS Statistics version 24.0 for Windows(IBM 
corp., Armonk, NY, USA). Normally distributed data are presented as means (standard 
deviation) and were tested using the unpaired t-test, while non-parametric data are 
presented as median [range] and were tested using the Mann-Whitney U test. Baseline 
differences in costs were checked with nonparametric bootstrapping, based on 1000 
replications.
Patients were excluded from the analysis when two or more questionnaires (cost and 
quality of life questionnaires) were missing at more than one time point. Missing values 
(i.e., EQ-5D-5L, EORTC QLQ C-30 and costs) were managed using mean imputations.
Incremental cost-effectiveness ratios (ICERs) and incremental cost utility ratios (ICURs) 
were estimated as the difference in costs between PEN and standard care divided by 
their differences in their effects or QALYs resulting in the costs per improved quality 
of life or costs per QALY. To quantify the uncertainty around the ICER, non-parametric 
bootstrapping was conducted in Microsoft Excel (5000 simulations).
Cost-effectiveness acceptability curves (CEAC) were used to present the results of the 
bootstrapping. A CEAC is a graphic representation of the uncertainty in differences in 
costs and effects between the two groups, showing the probability of an intervention 
being cost-effective for a wide range of threshold values. In the Netherlands, the council 
for Public Health and Healthcare proposed an informal ceiling ratio for the QALYs 
between €20,000 and €80,000 per QALY, depending on the burden of the disease.19
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Two one-way sensitivity analyses were performed to test the robustness of the results. 
The first analysis assessed the impact of imputation, thus included complete case only. 
Patients with missing variables were dropped from the analysis leaving only complete 
cases. A total of 183 patients (94 patients in the PEN group and 89 patients in the 
standard care) were included for both complete case cost-effectiveness analysis and 
cost utility analysis
The second analysis assessed the effects of including the excluded patients in the cost-
effectiveness analysis due to non-malignant nature of their disease (n=15). Fifteen patients 
were excluded in the base case cost-effectiveness analysis due their non-malignant 
tumor. A second sensitivity analysis was performed including these cases (n=233).
5.4. RESULTS
5.4.1. Baseline characteristics
Between August 2014 and August 2017, 265 patients were included in the original trial 
(n= 132 in the PEN group and n=133 in the standard care group). Of this, 259 patients 
(97.7%) completed the questionnaires at baseline, 224 (84.5%) patients completed 
postoperatively at 3 months and 216 (81.5%) patients completed at 6 months. Thirty-
two patients with missing questionnaires at least at two time points were excluded from 
the analysis. Furthermore, 15 patients with a non-malignant disease were excluded 
from the EORTC analysis. Ultimately, 233 patients were included in cost-utility analysis 
(120 patients in PEN group and 113 patients in standard care group) and 218 patients 
in the EORTC base case analysis and cost-effectiveness analysis (116 patients in the PEN 
group and 102 patients in the standard care group).
5.4.2. EORTC QLQ-C30 scores and utilities
There were no significant differences between the groups in any functioning, symptom 
or quality of life scales. Most scores (except the emotional functioning score) and 
utilities at 3 and 6 months deteriorated in both the groups in comparison with scores 
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5.4.3. Costs
The total societal costs in the 6 months following the surgery were €14,673 and 
€11,974 for the PEN and standard care group respectively, although non-significance 
was observed (p=0.109). Hospital stay costs and costs due to productivity losses were 
€2,853 versus €2,089 at p=0.194 and €3,205 versus €1,897 at p=0.130 for the PEN and 
standard care group respectively. The cost distribution of the two groups is shown in 
Table 2.
Table 2. Resources used and mean costs with bootstrapped 95% confidence intervals during 
the 6-month period
5.4.4. Cost-effectiveness and cost utility analysis
Concerning the global quality of life, the intervention resulted in an additional cost 
of 2,699 and a lower global quality of life. The ICER was estimated inferior at -€6,276 
(11,974-14,673/77.52-77.09) per point increase of global quality of life. With respect 
to the QALY, the intervention resulted in an additional cost of €2,941 and a marginal 
increase in QALY (0.003). The ICUR was estimated at €980,333 (14,633-11,692/0.432-
0.429) showing that the intervention is not a cost- effective treatment compared 
with the standard care. The marginal additional benefit on QALY produced by the 
intervention comes at an high additional cost of €2941. Results of bootstrap replications 
of ICERs/ICURs are presented in Figure 1 and Figure 2 which presents the difference in 




Figure 1. Cost-effectiveness of perioperative enteral nutrition versus standard care per point 
increase in global quality of life. QoL, quality of life.
Figure 2. Cost-effectiveness plane of perioperative enteral nutrition versus standard care per 
point increase in QALY gained. QALY, quality-adjusted life years.
The probability that the PEN is cost effective given different ceiling ratios, as presented 
in CEACs is shown in Figure 3. In terms of QALYs, if the willingness to pay is €50,000 per 
QALY gained, the probability that PEN would be cost effective is 9% (Figure.4).
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The results of sensitivity analysis were similar to the base case analysis. Excluding the 
imputed cases or including the non-malignant cases (with respect to global quality of life) 
did not increase the probability of PEN being cost effective. The results of the sensitivity 
analysis for cost-effectiveness and cost utility analysis are summarised in Table 3.
Figure 3. Cost-effectiveness acceptability curve of costs per point increase in global quality of 
life. WTP, willingness to pay; ICER, incremental cost-effectiveness ratio.
Figure 4. Cost-effectiveness acceptability curve of costs per QALY gained. WTP, willingness to 
































































































An economic evaluation of perioperative enteral nutrition in patients undergoing colorectal surgery
5.5. DISCUSSION
The study aimed to estimate the cost-effectiveness of PEN in patients undergoing 
colorectal surgery. Based on this trial data, PEN is not cost effective compared to usual 
care. It even increases the societal costs while not contributing in improving the quality 
of life in patients after colorectal surgery.
Although, there is no definite willingness to pay threshold known for improvement 
on the global quality of life scores, the estimates show that intervention was <41% at 
various threshold values and hence the probability of intervention being cost effective 
is low. Regarding QALYs, the probability that PEN being cost effective at a threshold of 
50,000 was only 9% which is not a promising estimate.
There was a substantial increase in the paid home care costs in the intervention group. 
PEN also resulted in higher societal costs. This may be due to increased hospital stay 
costs and productivity costs. We hypothesize that this finding may be linked to the 
(unexpected) increased rate in complications (such as pneumonia). This finding was 
not in line with a recent study by Rinninella et al 20.
In a retrospective analysis of patients consequently enrolled in an intervention group 
[ERAS (Enhanced Recovery After Surgery)+Nutricatt protocol] were comparing with 
patients treated according to standard ERAS protocol. The Nutricatt protocol consisted 
of nutritional prehabilitation before surgery and in the perioperative period. Here, a 
significant decrease in the hospital costs, complication associated costs and length of 
stay in the intervention group was found 20.
However, comparing the study by Rinninella with our study may not be completely 
appropriate due to important differences between the studies regarding (A) Comparison 
with the control group (retrospective cohort versus randomization), (B) Nutritional support 
(starting from 3 weeks before admission, pre- and postoperative and one month outpatient 
visit versus perioperative nutritional supplement), (C) composition of the nutritional 
supplements (oral diet versus lipid enriched nutrition in the perioperative period).20
In the current study, there was no improvement in the HRQoL scores. This may again 
be explained by the fact that the postoperative complications did not improve after the 
surgery and reducing the complications may limit the decrease in QoL after surgery; 
however this could not be demonstrated in our data.
The primary strength of this analysis is that patient level data from a randomized 
controlled trial was used. In addition, the economic evaluation was performed from 




There are however some limitations in the study. 1. The cost elements for all the 
participating centers reflect the reference prices from the Netherlands . 2. The use 
of patient reported questionnaires may have resulted in recall bias. 3. The study was 
conducted as a trial-based economic evaluation which may limit the generalizability 
of the results.21 4. Sample size was limited by exclusion of patients in the initial group 
who did not complete questionnaires at least at two time points. Additionally, a power 
analysis based on costs and HRQoL was not performed and this could potentially explain 
the non-significance of some results. 5. Since the patients were administered with 
questionnaires at baseline, 3 months and 6 months, it was impossible to do an analysis 
and check the economic impact at 1 month postoperatively where the effects could 
potentially be higher.
In conclusion, this trial-based economic evaluation suggests that PEN is not cost 
effective compared to usual care and does not confer a beneficial effect in HRQoL or 
utilities. Further studies are needed to confirm this finding and also to elucidate whether 
subgroups may benefit from this intervention.
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Aims: Following (minimally invasive) esophagectomy, patients often rely on tube feeding, 
since oral intake is often delayed. Consequently, additional support by a dietician and 
home care is needed until oral intake is commenced. In this study, the effects of direct 
start of oral feeding compared with tube feeding following an esophagectomy was 
evaluated on treatment costs and health-related quality of life (QoL).
Methods: Patients undergoing a minimally invasive esophagectomy were randomized in 
the NUTRIENT II study between controls (nil-per-mouth during 5 days and subsequent 
tube feeding) and a group in whom oral feeding was started directly postoperatively. 
Total hospital costs (including readmission and outpatient costs) and home care data 
for a period of 6 months after surgery were analyzed. QoL (measured using EORTC-
QLQ-C30 and EORTC OG-25) was assessed preoperatively and 6 weeks, 12 weeks, and 
6 months postoperatively.
Results: A total 132 patients were included (n=65 direct oral feeding group and n=67 
control group). Mean patient hospital costs were €26,014 in the intervention group over 
a 6-month period compared to €26,989 in the control group (p=0.825). Furthermore, 
people with direct oral feeding required significantly less home care assistance; i.e. 23 
(48.9%) intervention patients versus 37 (77.1%) control patients (p=0.004). Also, QoL 
in patients with direct oral feeding progressed more quickly when compared to the 
control group.
Limitations: Hospital costs were derived from a single hospital unit whereas costs from 
all the participating units may be a better reflection of the cost deviation. Availability 
of home care data was limited, leading to difficulty in detecting differences in costs.
Conclusion: This study suggests that direct oral feeding leads to similar total costs and a 
significantly reduced need for home care assistance. Furthermore, QoL in intervention 
group increased more quickly when compared to the control group.
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6.1. INTRODUCTION
Esophageal cancer is the sixth leading cause of cancer-related mortality and the 
eighth most common cancer worldwide.1 The incidence of esophageal cancer in the 
Netherlands and other Western countries is increasing rapidly.2-4 In the Netherlands, 
this is growing at a rate of roughly 400% in the recent years from 684 diagnoses in 
1989 to 2,500 in 2018.5, 6 A total of 2,536 new cases were identified in 2019.7 This is due 
to the increasing prevalence of known risk factors such as obesity, gastroesophageal 
reflux disease and smoking.8, 9 The Dutch healthcare costs for esophageal cancer care 
are expected to increase in the future with the increasing incidence and the improved 
neoadjuvant and surgical treatment.10 Esophagectomy remains the cornerstone in 
esophageal cancer treatment. Postoperative complications following an esophagectomy 
are substantial and associated with a prolonged hospital stay, increased resource use 
and a reduced quality of life (QoL).11, 12
Enhanced recovery after surgery (ERAS) protocols that aim to improve postoperative 
recovery after an esophagectomy and thereby reducing the cost burden, are more 
frequently implemented.13 Although early start of nutrition is an essential part 
of ERAS, oral intake is often delayed for at least five days in patients undergoing 
an esophagectomy because of fear of increased complications. Recently it was 
demonstrated that direct oral feeding was well tolerated and resulted in a similar 
functional recovery and complication rate compared to standard of care.14 Patients in 
the intervention group directly started a oral diet whereas patients in standard of care 
received nil-by-mouth for the first 5 days after surgery and tube feeding.
The aim of the current study is to assess treatment costs (including need for home 
care) and QoL in patients that started oral feeding directly following minimally invasive 
esophagectomy (MIE) compared to patients receiving standard of care.
6.2. METHODS
For this study, we used data of patients participating in the NUTritional Route In 
Esophageal Resection Trial (NUTRIENT) II study.14 The NUTRIENT II study was approved 
by the Medical Ethics Committee United (MEC-U) and registered at ClinicalTrials.gov with 
the registration number NCT02378948 and at the Dutch trial registry with registration 
number NTR4972. The NUTRIENT II study was a multicenter prospective open-label 
randomized controlled trial performed at two hospital units in the Netherlands and one 
hospital in Sweden between October 1, 2015, and May 14, 2018. The trial was designed 
to investigate the effects of direct oral feeding versus standard of care on functional 
recovery following esophagectomy. Inclusion criteria were patients aged 18 or older, 
undergoing elective minimally invasive esophagectomy for cancer with intrathoracic 




anatomical abnormalities), inability to place a feeding jejunostomy, inability to provide 
written consent, swallowing disorder, achalasia, Karnofsky Performance Status <80 and 
malnutrition.
Patients in the direct oral feeding group received a liquid/ purified diet directly 
postoperatively with a daily inclining volume.14 On postoperative day (POD) 20, a solid 
diet was started. In these patients a jejunostomy was inserted and used only when oral 
intake was neither possible nor sufficient. Patients in the control group received tube 
feeding via jejunostomy and were only allowed sips of water up to 250cc for the first 4 
days and then gradually expanded their oral intake similarly to the intervention cohort.
All patients provided written informed consent. Data on hospital costs, home care usage 
and costs, and health-related QoL of patients were analyzed. Quality of life data was 
obtained using questionnaires (patient reported) whereas cost data for each patient 
was obtained using electronic hospital system (i.e. individual data separately recorded 
for each patient in the clinical trial; patient level). In the original trial, a total of 132 
patients were included of which 65 patients in the direct oral feeding group and 67 
patients in the standard of care group. In order to adequately analyze the costs in this 
study, data was only gathered for the Dutch centers (direct oral feeding, n=47 versus 
control, n=48) Hospital cost analysis, home care usage and cost analysis were based on 
patients from one hospital and region (the Catharina Hospital from Eindhoven (n=95).
6.2.1. Hospital costs
Hospital costs were determined by retrospectively extracting financial data from the 
electronic hospital system. Hospital costs were defined as all costs made during the 
initial admission (i.e. surgery costs and admission costs) as well as readmission and 
costs at the outpatient clinic. Surgery costs were based on the operating room costs 
(depicted by the duration of surgery and a fixed starting rate) and operating room 
personnel costs. Admission costs included costs made for surgical ward and/or intensive 
care unit stay, charges for parenteral and tube feeding, and postoperative diagnostic 
procedure. Costs of readmission within 6 months after surgery due to complications 
related to the primary operation were also collected. Outpatient costs consisted out 
of costs made for outpatient visits and additional diagnostic procedures within the 6 
months after surgery. Monetary units are expressed in Euros (€).
6.2.2. Home care
Routine home care after an esophagectomy consisted of cleaning of the jejunostomy, 
flushing of the jejunostomy tube and connection of the jejunostomy tube to the feeding 
pump. Since, tube feeding is the main denominator for patients requiring home care 
after esophagectomy, data regarding tube feeding, home care assistance and costs 
for a period of 6 months following surgery were requested from the home care 
organizations. Patients requiring additional care (rehabilitation including home care) 
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after discharge were scored as needing home care assistance, but excluded from home 
care cost analysis due to lack of availability of data. Data was gathered from home care 
organizations regarding the number of days receiving home care and corresponding 
home care costs. Based on the available home care costs, average costs of home care 
per day and total costs per patient were calculated. The average home care costs per 
patient were extrapolated to all patients receiving home care.
6.2.3. Health-related QoL
Health-related QoL was assessed pre- and postoperatively using the European 
Organization for Research and Treatment of Cancer (EORTC) Quality of Life 
Questionnaire(QLQ)-C30 (version 3.0), a validated questionnaire to measure the QoL 
in patients with cancer.15 Additionally, the EORTC QLQ-OG25 supplements the EORTC 
QLQ-C30 when assessing health-related QoL in patients with esophageal, junctional or 
gastric cancer. Questionnaires were administrated at baseline (up to two weeks prior to 
surgery), 6 weeks, 12 weeks and 6 months postoperatively. Missing data were imputed 
according to the EORTC guidelines.16
EORTC QLQ-C30 questionnaire is composed of 5 functional scales (physical, role, social, 
emotional and functional) and 3 symptom scales (fatigue, nausea/vomiting, and pain) 
and a global health status/QoL scale. Furthermore, it contains 6 single items (dyspnea, 
insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The QLQ-OG25 
has a functional scale (Body image) and symptom scales (dysphagia, eating, reflux, 
odynophagia, pain, anxiety, eating with others, dry mouth, trouble with taste and 
swallowing saliva, choked when swallowing, trouble with coughing, weight loss and 
hair loss). All of the scales and single-item measures range in score from 0 to 100. A 
high scale score represents a higher response level. Thus a high score for a functional 
scale, represents a high level of functioning, a high score for the global health status 
represents a high QoL, but a high score for a symptom scale/item represents a high 
level of symptomology/problems.
6.3. STATISTICAL ANALYSIS
All statistical analyses were performed using IBM SPSS Statistic Version 24 for Windows 
(IBM corp., Armond, NY, USA). Normally distributed data are presented as mean with 
standard deviation and tested using an independent T-test. Nonparametric data are 
presented as median with interquartile range and were tested using the Mann-Whitney 
U test. All initial analyses were performed using an intention-to-treat approach. Also, 
a per-protocol analysis on hospital costs was performed to explain the effect of 
complications after esophagectomy. In short, only patients adhering to any nutritional 
protocol (i.e. either direct oral feeding or control group) were compared to patients 
deviating from any nutritional protocol.14 Cost data were presented as mean, median 




bootstrapping based on 5,000 replications. Mean and median cost data were compared 
using the unpaired T-test and Mann-Whitney U test.
6.4. RESULTS
6.4.1. Clinical outcomes
Clinical outcomes of the NUTRIENT study have been previously published.14 Median 
age was 65 years, predominantly male with an adenocarcinoma (77/95) of the distal 
esophagus (58/95). Functional recovery was comparable for both groups (7 in the 
intervention versus 8 days in the control group). Furthermore, the total postoperative 
complication rate was similar between groups (43.1% in intervention group versus 
50.7% in control group).
6.4.2. Hospital costs
Total mean costs after an esophagectomy were €26,014 in direct oral feeding group 
and €26,989 in the control group (p=0.825) and mostly determined by initial admission 
costs; see Table 1 for hospital costs in the 6 months following surgery.
Patients who adhered to any nutritional protocol (i.e. direct oral feeding or standard 
of care) to patients who deviated from any nutritional protocol, had significantly lower 
admission (€10,767 versus €30,913; p<0.001), readmission (€2,697 versus € 4,097; 
p=0.525) and total hospital costs (€19,258 versus €40,777; p<0.001). Surgery (€4,096 
versus €4,084; p=0. 914) and outpatient costs (€1,697 versus €1,682; p=0.976) were 
similar in the intervention and control group.
6.4.3. Home care
Tube feeding at hospital and home was required in 18 out of 47 intervention patients 
(38.3%) and in all patients receiving the standard of care. The median number of the 
days patients receiving tube feeding was significantly shorter in the intervention group 
(0 days [IQR 0-41]) when compared to the control group (28 days [IQR 21-50], p<0.001).
The need for home care assistance was significantly lower in the intervention group; 
23 patients (48.9%) compared to 37 patients (77.1%) in the control group (p=0.004). 
One patient in the intervention group and two patients in the control group required 
additional care after discharge, thus were excluded from home care cost analysis. 
Data regarding the length of home care assistance was only available in 32 (53.3%) 
patients and home care costs were known for 14 (23.3%) patients. Average home care 
cost was estimated on €37.34 per day and €1,310.31 per patient. Home care costs 
in the intervention group were estimated €28,826.39 (€1310.31*22) and €45,860.16 
(€1310,31*35) in the control group respectively (see Table 2).
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In total, 126 (95%) patients completed the preoperative baseline QoL questionnaire, 
110 (83%) patients completed the questionnaire at 6 weeks, 113 (85%) patients at 12 
weeks and 100 (75%) patients at 6 months postoperatively. As a result, a total of 118 
patients completed the questionnaires at two or more time points (56 patients in the 
direct oral feeding group and 62 patients in the standard of care group).
QoL in the direct oral feeding increased quicker in time compared with QoL of 
patients in the control group (see Figure 1). Both groups had a score of 83 at 6 months 
postoperative. Global QoL score did not significantly differ between the intervention 
and control group for the 4 perioperative measurements (supplementary Table S1).
Insomnia score at 12 weeks postoperative showed a significantly lower median in the 
intervention group (p=0.041). At six months postoperative, significantly less patients 
from the direct oral feeding group experienced diarrhea (p=0.024). Also nausea/
vomiting (p=0.033), odynophagia (p=0.046) and trouble with taste (p=0.028) showed 
a significant difference while the median scores were similar. No other significant 
differences were observed between the groups. Complete health-related QoL scores are 
shown in supplementary Table S1 (QLQ-C30) and supplementary Table S2 (QLQ-OG25).
Figure 1. Global quality of life for patients receiving direct oral feeding (intervention) and stan-
dard of care (nil-by-mouth for 5 days and tube feeding, control). Baseline measurement was up 
to 2 weeks prior to surgery. Median with Interquartile range: Baseline direct oral feeding (DOF) 
62[50-75], standard of care (SOC) 66[50-75]; 6 weeks DOF 66[50-75], SOC 66[50-75]; 12 weeks 
DOF 75[66-83], SOC 66[66-83]; 6 months DOF 83[75-83], SOC 83[66-83].
113
Effect of direct oral feeding following minimally invasive esophagecotmy
6.5. DISCUSSION
This study suggests that patients starting with oral intake directly following 
esophagectomy had lower home care costs and progressed more quickly to a higher 
QoL than patients with nil-by-mouth for five days and tube feeding. Also, it was shown 
that total costs following esophagectomy are high and mainly determined by initial 
admission period and admission related costs.
To our knowledge, no other studies have compared direct oral feeding with tube feeding 
and nil-by-mouth directly after (minimally invasive) esophagectomy in terms of costs 
and quality of life. In the current trial, all patients were operated upon with a minimally 
invasive approach. Previous studies comparing MIE with open surgery have shown 
increased surgical costs, but lower postoperative costs in the MIE group, resulting 
in conflicting conclusions. Total costs17 and surgical costs11, 18 for MIE in the current 
trial were lower than the costs for the open or combined open and minimally invasive 
approach in other studies. Differences between studies could be explained by effective 
implementation of an ERAS protocol leading to an optimized postoperative care pathway 
and an acceptable complication rate that is reduced following a learning curve.13, 18-20 
Compared to the current results, Weindelmayer et al – only including open Ivor Lewis 
esophagectomies – found higher surgical costs (in contrast with previous studies stating 
surgical costs are higher in the MIE setting17) while admission costs were lower. Hospital 
costs in this study were slightly lower compared to a randomized trial by Hulscher et al 
of adenocarcinoma patients undergoing an open esophagectomy between 1994 and 
2000.21 A more recent study by Goense et al, found average hospital costs of €37,571 
from esophagectomy until 90 days after discharge. This is higher than in the current trial, 
in which the study period includes hospital costs from esophagectomy until 6 months 
postoperative.11 In multivariable analysis they found an increase in costs for female 
patients, age >70 year and several postoperative complications (anastomotic leakage, 
cardiac complications, chyle leakage and postoperative bleeding). Since the cohort of 
Goense et al consisted of more female patients with a higher age, and both the AL and 
chyle leakage rates were 10% higher, this could explain the difference found between 
studies. Noteworthy, the significantly reduced chyle leakage rate found in the direct 
oral feeding group of NUTRIENT II trial14 and the succeeding analysis22 implies direct oral 
feeding could further reduce costs in these patients. Importantly, the learning curve 
was surpassed, thereby reducing the complication rate and complication-related costs.
In line, hospital costs for patients deviating from their nutritional protocol – which 
can be regarded as a proxy for a (severely) complicated postoperative course14 – were 
significantly higher compared to patients abiding to their nutritional protocol in this 





The current standard of care is tube feeding via jejunostomy to ensure sufficient intake 
after esophagectomy. However, weight loss following esophagectomy occurs once 
tube feeding is stopped23 regardless of the postoperative feeding regimen (oral vs. 
enteral)24. Moreover, the need for prolonged routine feeding jejunostomy for enteral 
nutrition is being questioned25-27 due to the frequent occurrence of jejunostomy-related 
complications23, 27, For example, bowel obstruction which is a severe jejunostomy-
related complication has been found to be significantly higher in patients that received 
enteral feeding via a jejunostomy.25, 28 Furthermore, a randomized pilot study for 6 
weeks home enteral nutrition found no clear cost-effectiveness of prolonged enteral 
feeding.29
In this study, total home care costs were based on data obtained for a smaller cohort 
and extrapolated to all patients needing home care assistance. Retrieval of home care 
data was challenging due privacy guidelines of home care facilities to share data, which 
resulted in the need for additional consent from all patients that participated in the 
trial. Despite the lack of a formal trial-based economic evaluation, the higher amount 
of patients receiving tube feeding and the longer period of tube feeding in the control 
group implies that this relative cost-effectiveness in absolute cost might be different, 
but always indicate superiority of the intervention group.
Hospital and home care cost analyses in this study imply that routine implementation 
of direct oral feeding after surgery could lead to a substantial reduction of costs and 
patient burden of home care organizations without compromising long-term outcomes 
on weight and even improving QoL.
QoL persistently improved after surgery in the direct oral feeding group whereas this 
improvement was not observed until six months after surgery in the control group. A 
possible explanation for this phenomenon could be that patients received tube feeding 
for a shorter period, or not at all. To our knowledge, only one other trial studying 
QoL in patients with early oral feeding after upper GI surgery by Sun et al reported a 
significantly improved global QoL for patients with early oral feeding after a McKeown 
esophagectomy.30 Two reasons could explain the difference with the current study: [1] 
patients in the control group received a naso-enteral feeding tube on POD 1, potentially 
leading to a diminished QoL caused by the discomfort of these feeding tubes which were 
not inserted in the intervention group, and [2] the first (global) QoL measurement was 
at 2 weeks postoperative. The significantly higher global QoL found by Sun et al at 2 
and 4 weeks postoperative equalized between their intervention and control group at 
8 weeks postoperative, and since the 8 weeks values are comparable with the global 
QoL found in the current study, this suggests our measurement of QoL at 6 weeks 
postoperative was too late to find a significant difference.
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When comparing global QoL with other studies, the population in this study performed 
better at 6 months postoperative. Kauppila et al showed a global QoL score of 63 (95% 
CI 57-69) at 6 months postoperative.31 Akkerman et al studied patients alive without 
disease recurrence at 1 year or more after surgery (median 36 months, range 12-75) and 
found a global QoL comparable with their used Dutch background population (mean 76 
[SD 19] vs. mean 78 [SD 17])32, but lower than the population at final study follow-up 
in this study. In disease-free patients, QoL is expected to restore within 6 months after 
surgery.33 The expectation is that the QoL in this cohort would further improve over 
time, since symptoms like fatigue, pain and coughing problems can persist for at least 
a year after surgery.34
Few symptoms were significantly different at long-term follow-up. Nausea/ vomiting 
and diarrhea at 6 months in the current trial were comparable with Kauppila et al.31 
Diarrhea at 6 months in the intervention group was already comparable with the 
symptom level of patients at 36m after surgery measured by Akkerman et al.31, 33
An important strength of this study was that patient level data was collected as a part of 
randomized controlled trial. However, this study also has some limitations. First, hospital 
costs were derived from a single hospital unit whereas costs from all the participating 
units may be a better reflection of the cost deviation. Second, limited availability of 
home care data which leads to difficulty to detecting differences in the costs. Lastly, the 
study was conducted based on a single center data which may limit the generalizability 
of the results.35 Further studies with a full economic evaluation comparing costs from a 
societal or health insurance perspective and using QALY as outcome would be needed 
to confirm the cost-effectiveness of the intervention.
In conclusion, implementation of direct start of oral feeding lead to a significant 
reduction of patients requiring home care assistance and related costs, and a quicker 
increase in quality of life while hospital costs were similar between groups. Since direct 
start of oral feeding resulted in a similar postoperative complication rate in multicenter 
international setting and significantly reduced complications in a center with a stable 
and acceptable postoperative complication rate, it may also reduce costs after adopting 
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The need for evidence-informed decision making in healthcare is becoming increasingly 
stronger as seen in the decision making process of new interventions to improve the 
recovery after colorectal and esophageal surgery. New developments in interventions 
might contribute to rising healthcare costs and compete for resources. Various new 
interventions that aim to reduce postoperative complications after colorectal and 
esophageal surgery are currently investigated. This dissertation focussed on nutritional 
interventions in colorectal cancer (CRC) and esophageal cancer (EC) patients.1, 2 
Nutritional support in these trials vary from oral or enteral nutrition few hours before 
and after surgery to direct intake after surgery with or without nasogastric tubes 
inserted in patients. These are relatively low cost interventions with potential large 
effects, but limited economic data is available for the effect on healthcare expenditures 
in these patients.3, 4
The aim of this dissertation was therefore to assess the cost-effectiveness of these 
interventions using data gathered in recent randomized controlled trials (RCT). In 
addition, we also aimed to estimate the burden of CRC and EC to understand the 
economic and quality of life implications on the patient and society. Burden of illness 
studies also support economic evaluations and provide important information for future 
economic analyses of new interventions. Next, a total of three trial-based economic 
evaluations with nutritional interventions were conducted with the aim to study their 
effects on postoperative complications, costs and quality of life.
More specifically, in part I of the dissertation, the magnitude of preoperative burden, 
specifically the costs and quality of life of CRC was assessed (chapter 2); next, the burden 
of postoperative complications of CRC was investigated including how postoperative 
ileus (POI) increase the inflammation, costs and quality of life (chapter 3). In part II, the 
results of three trial-based economic evaluations (chapters 4, 5, 6) evaluated the cost-
effectiveness of these new nutritional interventions (i.e. gum chewing in SANICS I trial, 
perioperative enteral nutrition in SANICS II trial and early oral feeding in NUTRIENT II 
trial) compared with standard care from a societal perspective.
This final chapter provides a summary of the main findings of this dissertation, discusses the 
methodological challenges and suggests implications for public health and policy making, 
as well as research recommendations on new nutritional interventions in CRC and EC.
7.1. Summary of main findings
Part 1 of this dissertation presented two studies conducted to understand the clinical 
and economic burden of CRC and its complications. Both studies were embedded in an 
international multicenter RCT (SANICS II). Patients from Dutch hospitals participating 
in the trial were the basis for estimating the preoperative burden of CRC in the 
Netherlands. For estimating the burden of complication (POI), all the patients included 
in the original trial were studied to assess its influence on recovery, costs and quality of 
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life. Costs and quality of life were assessed using the patient-reported questionnaires 
administered at specific time points during the trial process.
A retrospective cost of illness study (chapter 2) was conducted using a bottom-up 
prevalence based approach. It showed that the mean societal cost per CRC patient was 
estimated at €3,211 in the 3 months prior to surgery and the utility score of patient 
prior to surgery derived from EQ-5D was 0.88. Lack of prior research studies from the 
Netherlands on this topic led to inability to compare the results. However, when the 
results were compared with some international studies, the utility score was somewhat 
higher.5, 6 Comparison of the costs with previous international studies was hampered 
due to variation in valuing methodology and time period of estimation of costs.7-9
Then, the consequences of POI on recovery, costs and quality of life (chapter 3) were 
estimated. Clinical and economic outcomes were compared between patients with and 
without POI, and in particular patients with POI as a unique complication. Inflammatory 
parameters (C-reactive Protein levels) were increased in patients with POI compared 
to patients without POI. The results of this study regarding the rise of inflammatory 
markers in the blood following surgery are in agreement with a previous study by 
Boersema10 and other animal studies as discussed in chapter 3. Mean societal costs per 
patient with POI in this study were 38-47% higher at 3 months postoperatively similar 
to previous studies.11-13. Furthermore this study demonstrated that patients with POI 
have a higher chance of developing other complications and accompanied 9% increase 
in costs. Median utility scores were lower in the POI group at both 3 months (0.85 versus 
0.89; p=0.023) and 6 months (0.84 versus 0.89; p=0.017) demonstrating a long term 
burden of POI on patients.
In Part II of the dissertation, three economic studies were conducted to identify 
if nutritional interventions were cost effective (chapters 4, 5, 6). Chapters 4 and 5 
are embedded in the SANICS I and SANICS II trials respectively which are based on 
the hypothesis that nutritional interventions inhibit the vagus nerve and reduce 
postoperative complications.
Gum chewing as an intervention was first introduced in a pilot clinical study (SANICS I) 
 and the clinical results were positive showing advantages over the placebo group. 
Gum chewing significantly reduced POI (14/52 patients versus 29/60 patients) and 
anastomotic leakage (AL) (2/52 patients versus 8/60 patients) compared to placebo. 
However, the results of our trial-based economic evaluations alongside SANICS I were 
not conclusive about the economic value of gum chewing. No significant differences in 
overall hospital costs between groups were observed, however lower costs for ward 
stay were seen in the gum chewing group. Cost-effectiveness analysis resulted in ICERs 
expressed in costs per POI or AL. More than 50% of bootstrapped replications for 




major limitations in data availability, potentially limiting the conclusion of the study. 
For example, utilities were mapped from the QLQ-C30 questionnaires and it was not 
possible to estimate quality-adjusted life years due to non-standardization of the time 
point of administration of the questionnaires. There was also a significant number 
of missing quality of life questionnaires and therefore the results were based on a 
limited sample size (chapter 4). Postoperative gum chewing was not cost effective in a 
previous study when compared with standard care14 however, comparing the results of 
the current study with previous studies is complex due to variations in the timing of the 
gum chewing, clinical and economic outcomes and perspective of the cost calculation.14
A more comprehensive trial-based economic evaluation with the perioperative enteral 
nutrition (PEN) as the intervention was then conducted. This study included various 
questionnaires to collect cost and quality of life resources (chapter 5) during the trial 
horizon at baseline, 3 months and 6 months. Although the intervention was similar 
to SANICS I, the trial did not yield positive clinical results. Lack of clinical effect of 
PEN on postoperative complications in the trial could be due to various reasons such 
as adherence to ERAS protocols and inclusion of patients operated via laparoscopy. 
Nevertheless, we investigated the impact of the intervention on the costs and health-
related quality of life and found no significant differences in societal costs (€14,673 
versus €11,974; p=0.109) and global quality of life (83 versus 83; p=0.357). The gain in 
QALY was marginal (0.003) with an additional cost of €2,941 and the ICUR (incremental 
cost utility ratio) was estimated at €980,333. A previous study with nutritional 
prehabilitation indicated lower costs and length of hospital stay when compared to the 
current study however, differences in the control group, route of nutrition and length of 
perioperative nutritional period were observed and could also explain the difference.4
Finally, a third trial to study the postoperative recovery in EC patients with early oral 
feeding as the intervention was conducted (chapter 6). This trial demonstrated that 
direct oral feeding was well tolerated and resulted in a similar functional recovery and 
complication rate compared to standard of care. Mean hospital costs were similar 
between the groups (€26,014 in intervention versus €26,989 in control groups) which 
was lower when compared to previous studies.15, 16 The hospital costs in patients 
deviating from the nutritional protocol were significantly higher when compared with 
patients that did not deviate from the protocol. Furthermore, it was observed that 
direct oral feeding significantly reduced the need for home care assistance (48.9% 
versus 77.1%, p=0.004) and the quality of life increased quicker when compared to 
control group. QoL in a previous study reported an improvement in patients with early 




Two important methods, namely the cost of illness study and trial-based economic 
evaluation, were used in this dissertation. This section addresses the methodologic 
challenges, strengths and limitations of these methods.
7.2.1. Cost of illness studies
Cost of illness studies are being conducted with the aim of highlighting the burden of 
the disease besides the usual epidemiological estimates such as incidence, prevalence, 
mortality or morbidity helping determine research priorities and providing baseline 
against which new interventions can be assessed.17, 18
7.2.2. Trial-based economic evaluations
Economic evaluations that compare the costs and outcomes of new interventions with a 
control intervention are used to inform decision makers on the efficient use of available 
resources. Trial-based economic evaluations area primary source of data on the cost- 
effectiveness of health technologies and they are used in health service decision making.
While we aimed to follow available recommendations for conducting cost of illness 
studies and economic evaluations, conduct of the studies faced some methodological 
challenges.
A first limitation is the lack of a standard methodology for extracting the primary patient 
data (resource use, unit costs and home care costs). Data on costs are difficult to obtain 
since hospitals do not isolate all costs, for example, home care costs. Considering 
privacy guidelines, all the patients that participated in the trial needed to be consented 
separately for any home care services that were used and mostly, this has to be done 
retrospectively. Additionally, it was difficult to obtain the consent from all the home 
care organizations as not all of them were familiar with the data retrieval process, 
moreover a large part of data was not being electronically maintained. (chapter 6). 
Furthermore, care organizations have separate and non-transparent agreements with 
healthcare insurance companies which makes this process of data retrieval tedious and 
extremely time consuming. Standardization of data gathering and agreement between 
care organizations and insurance companies for an uncomplicated data retrieval is 
necessary. Formulating an explicit protocol on methods for home care data extraction 
in cost studies as well as developing an e-health identifier for easy patient data retrieval 
would be favourable. Thus, we appeal for effective data sharing options to help achieve 
swift data acquisition in such studies. Adapting the regulations involving primary and 
economic patient information in clinical practice can be another solution, however this 




The next challenge concerns using the Dutch costing manual that provides guidance 
to researchers to perform and evaluate economic evaluations in the Netherlands.19 
The manual constitutes reference prices for commonly used healthcare consumption 
i.e. average unit costs. We, however, noticed that reference prices for some diagnostic 
procedures and therapies, for instance, MRI abdomen, dialysis, and radiotherapy, etc., 
within the healthcare sector were missing. Therefore, cost estimation for such procedures 
was complicated. We, therefore plea to introduce more items in the manual that would 
benefit researchers working on economic evaluations of various therapies. Relying on 
hospital tariffs and applying the tariff for these procedures can be a potential alternative.
Another important challenge is the use of nutrition as an intervention in our studies. 
20 A systematic approach or specific methodology to assess the impact of nutrition 
on health and health-related quality of life does not exist. Furthermore, it has been 
argued that nutritional interventions differ from the routine drug interventions as 
these are not completely stand-alone and an adjuvant to the medical treatment and 
have an interdependent nature. It is thus challenging to demonstrate the cause-effect 
relationship between medical nutrition and overall outcomes. 20 The sensitivity of 
quality of life instruments such as EQ-5D questionnaire could however be questioned.21 
Although the economic studies in this thesis were based on RCTs with a single 
independent factor, assessing the cost-effectiveness of medical nutrition is a new area 
within health economics. Performing economic analysis of such nutritional interventions 
with basic methodology developed for pharmaceutical products is likely to be inaccurate 
due to key issues concerning the study design, population and sample size. 20
New guidelines with a systematic approach in the field of medical nutrition outcomes 
research are being developed for better performance and judgement of medical 
nutrition outcomes research .20, 22 This can be done by appropriate guidance from 
nutritional specialists, epidemiologists and health technology assessment (HTA) experts.
Missing data and lack of standardization of administration of questionnaires further 
limited the results of some trial-based economic evaluation (chapter 4). A significant 
amount of data was missing and imputations were made to compensate for this, 
however, this may have compromised the validity of the trial results. Efforts to increase 
response rate is important. Optimization of handling of missing data during the planning 
stage of an RCT23, engaging the patients by inviting them to make self-reports of health 
needs, providing feedback of their progress and helping them perceive that their reports 
will actually serve a purpose23, 24 are a few methods to improve the response rates. 
Additionally, utility scores found in our studies were relatively high and assessing if the 
values are clinically meaningful was not possible without a proper comparison with general 
Dutch population. Utilities were derived from the Dutch tariff for EQ-5D-5L which could 
differ from the tariff from other countries. Utility values for general Dutch population 
are not known and it would be interesting to find such a comparison in the future.
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Efforts to increase the validity of the trials are needed. So, we recommend the inclusion 
of cost and quality of life questionnaires (EQ-5D) at several time points to compare the 
change in quality of life outcome from baseline to various postoperative time points.
7.3. Implications for decision making, clinical practice and further research  
recommendations
The results of the cost-effectiveness studies presented in this thesis were inconclusive 
with no significant differences in costs and quality of life. SANICS I study was further 
difficult to interpret due to limitations in the data.
Decision making
CRC and EC have been identified as a major public health problem in the Netherlands.25-29 
With continued screening procedures, the prevalence of CRC and EC is going to rise 
and the direct and indirect costs of treatment are expected to rise. Accordingly, a 
search for optimizing the CRC and EC management is crucial. By exposing the financial 
burden of the cancer and by exploring the cost-effectiveness of the new technologies 
in this patient population, the current studies (chapters 2,3,4,5, and 6) provide decision 
makers with information for health services planning. 30, 31
Part II of this dissertation suggested that the new technologies such as gum chewing, 
perioperative enteral nutrition and early oral feeding (chapters 4, 5 and 6) are safe and 
low cost although their cost-effectiveness cannot be demonstrated yet. Usefulness and 
value of information on cost-effectiveness should be recognized which will help in future 
decision making process. However further research with methodological improvements 
are needed to enhance the reliability of economic studies. Decision makers should 
consider research of such interventions in the management of CRC and EC. Developing 
(cost) effective interventions to improve treatment outcomes would be worthwhile.
Clinical Practice
Clinicians play a vital role in healthcare spending. It is important that clinicians consider 
both costs and effects of health interventions and deliver healthcare in cost-effective 
way. It is therefore important that clinicians understand the role of cost-effectiveness 
analyses for healthcare delivery and assess the quality of economic evaluations.32-34
Our findings provide evidence for clinicians regarding the economic implications of 
nutritional interventions in CRC and EC patients. The trial-based economic evaluations 
of SANICS I, SANICS II and NUTRIENT II studies (chapters 4, 5, 6) showed that gum 
chewing, perioperative enteral nutrition and early oral feeding are feasible and simple 
interventions. Exploring such innovative and inexpensive interventions to reduce 
postoperative complications might lead to a reduction in healthcare costs. Clinicians 





Several recommendations for further research emerge from this thesis. The search 
for cost-effective means for reducing the economic and clinical burden of CRC and EC 
should be fostered and our studies could serve as a basis for incorporating nutritional 
interventions. More research addressing the nutritional interventions (oral or enteral) 
at different time points (perioperative, few hours before or after surgery) with or 
without nasogastric tubes should be explored to study the impact on end points, such as 
hospitalization, morbidity, mortality, quality of life and its long-term cost-effectiveness. 
Modelling for long-term quality of life in colorectal and EC patients would also be 
interesting. A health economic model allows evidence from different sources to be 
synthesized so that an estimate of the long term costs and outcomes of nutritional 
interventions could be projected.
Research involving nutritional interventions is scarce and comparability of economic 
evaluations is difficult with the currently available literature since they differ in cost 
estimation methodologies and lack of standardized quality reporting particularly for 
nutrition related costs and health outcomes. Defining methodological and structural 
requirements for assessing the cost-effectiveness of nutritional interventions would 
be extremely worthwhile. To this extent, nutrition economics is a new branch in HTA 
which has been created by experts in the field of nutrition and health economics to 
explore and discuss the new guidelines for high quality economic data for nutrition. 
We support this platform and recommend addressing the methodological issues in the 
evaluation of nutritional interventions in future research. Furthermore, a collaboration 
of clinicians, nutritionists and qualified health economists to perform and interpret 
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Colorectal (CRC) and esophageal (EC) cancers are the most prominent and deadly 
cancers with high morbidity, mortality rates and increased healthcare expenditure. 
Postoperative complications such as postoperative ileus (POI) and anastomotic leakage 
(AL) are inevitable and they further reduce the functional capacity and quality of life 
in these patients.
The escalating clinical and economic burden of CRC and EC coupled with high costs of 
its management on one hand and limited health resources on the other hand, provide 
the rationale for fostering the search for cost-effective interventions for managing CRC 
and EC. Three randomized controlled trials were recently conducted with nutritional 
interventions such as gum chewing and perioperative enteral nutrition in CRC and early 
oral feeding in EC. In this dissertation, we provided an overview of cost-effectiveness of 
these interventions. In addition, the financial burden of CRC and EC, its complications 
and the quality of life was investigated.
Part I of this dissertation presented two studies conducted to assess the costs and 
quality of life of CRC and burden of its complications. In chapter 2, we explored the 
societal cost of illness of CRC and its drivers in the Netherlands. Our estimates revealed a 
3-month societal cost of €3,211 with 45.5% of this cost attributable to productivity costs 
highlighting the high financial burden of CRC on Netherlands society and healthcare 
system. In chapter 3, we explored the clinical and economic burden of postoperative 
ileus using the data from SANICS II trial. It was observed that patients with POI had 
increased inflammatory parameters, higher costs, lowered functioning, reduced 
quality of life and utility. When we compared utilities between patients who had only 
POI with patients without any complications, the effect was much more remarkable. 
Consequently, it was demonstrated that there is an association between inflammatory 
markers in blood and postoperative complications and that inflammation is elevated 
after manipulation of intestine.
Part II of this thesis informed specifically the cost-effectiveness of interventions tested 
in the new trials (SANICS I, SANICS II and NUTRIENT II). In chapter 4, we performed 
an economic evaluation alongside SANICS I trial and explored whether gum chewing 
could be a cost-effective intervention and determined its effect on hospital costs and 
health-related quality of life. Patients in the intervention group were asked to chew 
gum at least three hours prior to surgery and again three hours after the end of surgery. 
Patients in control group received placebo dermal patch three hours prior to surgery. 
Mean costs for ward stay were significantly lower in the gum chewing group however 
no significant differences were seen in the overall in-hospital costs or utilities. Cost-
effectiveness analysis for two postoperative complications POI and AL was determined. 
Gum chewing was seen to be dominant with lesser costs and more effects in more than 
50% of the simulations for both POI and AL.
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An economic evaluation was then performed alongside SANICS II trial from a societal 
perspective as seen in chapter 5 of this thesis. SANICS II was a multicentre randomized 
controlled trial conducted in three Dutch and two Danish hospitals. Lipid enriched 
nutrition was administered just before, during and after the colorectal resection to 
patients in intervention group and compared to patients in standard care or no nutrition 
group. Societal costs, quality of life scores and utilities between the two groups did not 
differ significantly. Cost-effectiveness analysis for global quality of life was determined 
and it was observed that intervention resulted in an additional cost of €2,699 and a 
lower quality of life. We also observed that the intervention resulted in an additional 
cost of €2,941 for a marginal increase in QALY (0.003) suggesting that the intervention 
was not cost-effective compared to usual care. In chapter 6, we assessed the effect 
of direct oral feeding following minimally invasive esophagectomy on treatment costs 
and health-related quality of life. This study was performed for the NUTRIENT II trial 
population. NUTRIENT II was a multicenter prospective randomized controlled trial 
performed at two hospital units in the Netherlands and one hospital in Sweden. The trial 
studied effect of early oral feeding in comparison with standard of care (tube feeding) 
on functional recovery following esophagectomy. We observed that direct oral feeding 
resulted in similar costs (€26,014 versus €26,989, p=0.825) but significantly reduced the 
need for home care assistance (48.9%) in comparison with the standard of care group 
(77.1%), p=0.004. We also observed that patients in the direct oral feeding progressed 
more quickly/steadily to recovery.
In conclusion, the findings of this dissertation present high quality evidence on economic 
implications of nutritional interventions in CRC and EC and further provide insights for 










This chapter discusses the societal value of the results found in this thesis for 
researchers, patients, healthcare professionals and policy makers. Moreover, the efforts 
made to disseminate the knowledge gained from this thesis are described.
Colorectal cancer (CRC) and esophageal cancer (EC) are gastrointestinal cancers 
with high incidence and mortality rates (estimated in the Netherlands at 14,921 
incidences and 6,396 mortality cases in colorectal cancer; 2,458 incidences and 2,046 
mortality cases in esophageal cancer in 2018).1 Postoperative complications (such as 
postoperative ileus and anastomotic leakage after colorectal surgery and anastomotic 
leakage and pulmonary complication in EC) are inevitable despite advances in surgical 
techniques and occur in about 30-46% of the patients.2-7 Postoperative complications 
are associated with increasing costs and also negatively affect the quality of life.8 In 
2017, the Dutch government spent 597 million euro on CRC (representing 0.5% of the 
total healthcare costs in the Netherlands) and the Dutch healthcare costs for EC were 
estimated at 124 million euro in 2007.9 In this context, it is important to identify cost-
effective interventions to reduce economic burden of CRC and EC and the associated 
complications.
This dissertation had the objective to assess the economic burden of colorectal and 
esophageal cancer and to estimate the cost-effectiveness of three interventions recently 
assessed in trial-based economic evaluations.
Relevance for researchers
The findings in this thesis gives details on burden of costs in CRC and EC. This thesis also 
provides an overview of the current economic evaluations conducted in CRC and EC 
which indirectly focusses on: First, methodological challenges that were identified in the 
conduct of trial-based economic evaluations. Missing data and lack of standardization 
of administration of questionnaires limited the results of some trial-based economic 
evaluations. Optimization of handling of missing data during the planning stage of 
a randomized controlled trial (RCT) and involving the patients in their progress and 
providing them feedback are recommended to increase the response rate and limit 
the missing data. Furthermore, we recommend inclusion of cost and quality of life 
questionnaires at several time points to compare the outcomes from baseline to 
different time points; Second, nutrition as an intervention has some intrinsic challenges 
due to lack of specific methodology to assess the impact of nutrition on health and 
health-related quality of life. Cost-effectiveness of medical nutrition is a new area in 
health economics and performing economic analysis of such interventions without a 
systematically developed methodology is likely to be inaccurate.10 Developing new 
guidelines for better judgement of nutritional interventions is essential.10, 11
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Relevance for patients and healthcare professionals
This thesis revealed the high burden of postoperative complications on both patients 
and family of patients with CRC and EC. In particular, this thesis shows, not only which 
healthcare costs are related to hospital consumption and productivity but also the 
percentage of reported problems in each dimension (mobility, self-care, usual activity, 
pain/discomfort, and anxiety/depression). We also show that complications result in 
higher costs (e.g. postoperative ileus resulted in 38% to 47% higher costs) with lower 
quality of life not only at 3 months but also at 6 months.
The cost-effectiveness results of the economic evaluation in this thesis concerning two 
perioperative nutritional methods (perioperative nutritional intervention and gum 
chewing) were not promising. Perioperative enteral nutrition was more expensive and 
less or little more effective than the control intervention which led to high incremental 
cost-effectiveness ratios on the two outcomes (global quality of life and quality-adjusted 
life years). Although, gum chewing was less expensive and more effective in reducing 
the postoperative ileus and anastomotic leakage, it remained a challenge to conclude its 
cost-effectiveness due to limitations in the current data. Evidence in our study showed 
that direct oral feeding after esophagectomy required less home care and was equally 
expensive and showed improvement in several outcome measures (e.g. quality of life) 
however, further research is essential.
The methodological studies described in this thesis are directly relevant to the patients 
and healthcare professionals. The studies aimed to decrease the complication rate and 
therefore increase the quality of life in the patients. In addition, it is relevant for patients 
and healthcare professionals to know what the (cost-) effectiveness of intervention 
aiming to treat CRC or EC is. Although it is unrealistic to assume that every patient or/
and healthcare professional understands the results of the studies in this thesis, it is 
possible to present the overall conclusion in a comprehensible way.
Relevance for policy makers or healthcare insurance companies
This thesis provides important messages for policy makers (e.g. the Dutch Ministry 
of Health or healthcare providers) and health insurance organizations (such as 
‘Zorginstituut Nederland’). Healthcare policy makers are urged to make complex 
decisions in the context of increasing availability of new and innovative interventions 
and treatments on one hand, and scarce resources on the other hand. Therefore, it is 
crucial to provide them with evidence on potential cost-effectiveness of healthcare 
interventions. Evidence from this thesis provides the healthcare policy makers with 
the following messages: First on the clinical and economic burden of CRC and EC and 
of the complications; second on the challenges of nutritional interventions and absence 
of cost-effectiveness results for such interventions; and third on the significance of a 
reliable cost-effectiveness analysis with appropriate data collection during RCT.
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It is important to look at the (cost-) effectiveness of a treatment for the policy makers 
and insurance companies to make a decision on what to reimburse. Regarding the 
SANICS I study, although it was difficult to certainly conclude the cost-effectiveness of 
gum chewing, reduction in rate of complications reduced the costs for ward stay. The 
NUTRIENT II trial demonstrated similar total costs and significantly reduced the need for 
home care assistance. This may make policy makers or healthcare insurance companies 
willing to investigate further into the perioperative nutritional interventions and which 
patients are best able to benefit from these interventions.
Dissemination
To simulate the dissemination among fellow researchers, the results of all the five studies 
described in this thesis are published in international journals. Besides international 
publications, results of the studies in this thesis have been presented at international 
conferences such as the European Health Economics Association (EUHEA), 2018 as well 
as locally at Maastricht University Medical Center, Maastricht and Catharina hospital, 
Eindhoven (wetenschapsdag 2017). Other intended measures to share the findings of 
this research are face to face meetings with the knowledge users and communicating 
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